Protein,Protein_definition,Trait_category,Trait,sample_size,Estimated_effect,se,lowerCI,upperCI,Pvalue
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1050.Time spend outdoors in summer,45269,0.0175426126968533,0.0146801762348798,-0.0112305327235111,0.0463157581172177,0.232098559733313
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1060.Time spent outdoors in winter,39521,-0.0147215630230955,0.0165343995577568,-0.0471289861562989,0.0176858601101079,0.373278196525845
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X1070.Time spent watching television (TV),47580,0.100239967462223,0.0147654239490654,0.071299736522055,0.129180198402391,1.14368972632532e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X1080.Time spent using computer,39468,-0.0157053324723112,0.0152584344844851,-0.0456118640619019,0.0142011991172796,0.303350394714872
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X1090.Time spent driving,34273,0.0372686678832933,0.016610336644919,0.00471240805925192,0.0698249277073346,0.0248578562276826
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1160.Sleep duration,50132,0.0103724026174086,0.013335325264346,-0.0157648349007096,0.0365096401355267,0.436682348040345
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#0.Location of pain during the past week_None of the given areas,16773,-0.00145845401137897,0.0155951085815543,-0.0320248668312255,0.0291079588084675,0.92549160722175
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#1.Location of pain during the past week_Left shoulder,16773,0.0360602002578335,0.0152035399697523,0.00626126191711893,0.0658591385985481,0.0177115009082147
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#10.Location of pain during the past week_Upper right leg,16773,0.0188095559937198,0.0173815805239612,-0.0152583418332442,0.0528774538206839,0.279199441980514
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#11.Location of pain during the past week_Lower left leg,16773,0.0113825107191893,0.0177835801201742,-0.0234733063163521,0.0462383277547307,0.522144081678178
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#12.Location of pain during the past week_Lower right leg,16773,0.0191277263627117,0.0181207939272221,-0.0163890297346435,0.054644482460067,0.291180940428113
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#13.Location of pain during the past week_Left jaw pain,16773,-0.0142526408294876,0.0384058617901573,-0.0895281299381958,0.0610228482792207,0.710563368508189
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#14.Location of pain during the past week_Right jaw pain,16773,-0.0368822682119354,0.0401689955339465,-0.11561349945847,0.0418489630345997,0.358539155720971
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#15.Location of pain during the past week_Chest pain,16773,-0.0376166209324408,0.027300847471392,-0.0911262819763691,0.0158930401114874,0.168266325230954
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#16.Location of pain during the past week_Abdomen,16773,-0.0179448836693389,0.0200379885439146,-0.0572193412154116,0.0213295738767338,0.370509664614749
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#17.Location of pain during the past week_Neck pain,16773,0.0214227295334561,0.0137291894003113,-0.00548648169115402,0.0483319407580663,0.118689386431193
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#18.Location of pain during the past week_Upper back,16773,0.0257923898989421,0.0198943579274983,-0.0132005516389546,0.0647853314368388,0.194832296770686
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#19.Location of pain during the past week_Lower back,16773,0.00852847944945841,0.0111133530338279,-0.0132536924968443,0.0303106513957612,0.442849601559141
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#2.Location of pain during the past week_Right shoulder,16773,-0.00903863888321882,0.0144270762675801,-0.0373157083676759,0.0192384306012382,0.530992134146927
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#3.Location of pain during the past week_Upper left arm,16773,0.0266257454083389,0.0213631804369907,-0.0152460882481628,0.0684975790648406,0.212657721889991
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#4.Location of pain during the past week_Upper right arm,16773,0.00534742667272674,0.0202194884961941,-0.0342827707798137,0.0449776241252672,0.791421848148405
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#5.Location of pain during the past week_Lower left arm,16773,0.0105211169411925,0.0270326147244416,-0.042462807918713,0.063505041801098,0.69713251114416
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#6.Location of pain during the past week_Lower right arm,16773,-0.0369562676025511,0.0255530436101459,-0.087040233078437,0.0131276978733348,0.148123839085381
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#7.Location of pain during the past week_Left hip,16773,0.00784528000896517,0.0156252709299839,-0.0227802510138033,0.0384708110317337,0.615611362928726
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#8.Location of pain during the past week_Right hip,16773,0.0167907885430673,0.0148666494322096,-0.0123478443440635,0.0459294214301982,0.258734104408859
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#9.Location of pain during the past week_Upper left leg,16773,0.0296902851361794,0.0184745754470569,-0.00651988274005218,0.065900453012411,0.108053706507901
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120040.Fatigue severity over the past week,16784,0.0874921965460547,0.0241432393008083,0.0401714475164705,0.134812945575639,0.000291074626552783
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120041.Waking unrefreshed severity over the past week,16784,0.0654572695615084,0.0239377046334485,0.0185393684799493,0.112375170643068,0.00625437438394968
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120042.Cognitive symptoms severity over the past week,16784,0.065966348531571,0.0258050959061568,0.0153883605555037,0.116544336507638,0.0105869980276995
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120098.Mobility problems today,16793,0.0441214564047013,0.0281907111403696,-0.0111323374304232,0.0993752502398258,0.117576874930452
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120099.Self-care problems today,16793,0.00429440199104555,0.0438443536409321,-0.0816405311451813,0.0902293351272724,0.921975927720681
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120100.Problems doing usual activities,16793,0.0231267564230498,0.0269094030948506,-0.0296156736428574,0.075869186488957,0.390115438251764
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120101.Pain or discomfort today,16793,0.0397573589993945,0.0240751801488284,-0.00742999409230918,0.0869447120910982,0.0986789768269886
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120102.Anxiety or depression today,16793,0.0410740661038854,0.0291835392217891,-0.0161256707708213,0.098273802978592,0.159315630219958
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120103.Scale to indicate how health is today,16740,-0.00358571931867355,0.0048245582510636,-0.0130418534907582,0.0058704148534111,0.457357538349587
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120104.Little interest or pleasure in doing things over the last two weeks,16754,0.040038819757429,0.0294276114206899,-0.0176392986271232,0.0977169381419812,0.173662624923693
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X120105.Feeling down, depressed, or hopeless over the last two weeks",16728,0.0168194951191176,0.0303751405924924,-0.0427157804421676,0.0763547706804028,0.579774011736791
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X120106.Trouble falling or staying asleep, or sleeping too much over the last two weeks",16763,0.0562764927840624,0.0238901504900419,0.00945179782358015,0.103101187744545,0.0185025024420508
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120107.Feeling tired or having little energy over the last two weeks,16762,0.070931656102486,0.0245546034781935,0.0228046332852268,0.119058678919745,0.00387295055666578
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120108.Poor appetite or overeating over the last two weeks,16771,0.0873575850799862,0.0314505722602885,0.0257144634498209,0.149000706710152,0.00548203181401709
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120109.Feeling bad about self over the last two weeks,16727,0.0439275433570705,0.0317006149280645,-0.018205661901936,0.106060748616077,0.165857008378285
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120110.Trouble concentrating over the last two weeks,16770,0.0496436584068998,0.0316052846976016,-0.0123026996003992,0.111590016414199,0.116262132554288
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120111.Moving or speaking slower or faster than usual over the last two weeks,16754,0.0941851720379685,0.0457307438302973,0.00455291413058588,0.183817429945351,0.0394561341327926
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120112.Thoughts of being better off dead or of hurting self over the last two weeks,16680,0.0786332345181402,0.0627066980627322,-0.0442718936848149,0.201538362721095,0.209865188674594
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X120113.Level of difficultly depression has made to do work, take care of things at home, or get along with other people",11682,0.0401683251064817,0.0328803519547685,-0.0242771647248646,0.104613814937828,0.221864200969029
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1269.Exposure to tobacco smoke at home,45351,0.0543055286138811,0.0322499496491573,-0.00890437269846722,0.117515429926229,0.0922088491005669
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1279.Exposure to tobacco smoke outside home,42326,0.0483172888413785,0.0199217843826028,0.00927059145147711,0.0873639862312799,0.0152978129806902
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X1289.Cooked vegetable intake,48694,-0.0121257622850625,0.0139727387483413,-0.0395123302318115,0.0152608056616865,0.38549950286999
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X1299.Salad  or  raw vegetable intake,47385,-0.0946059841986886,0.0146325806734997,-0.123285842318748,-0.0659261260786293,1.01988281439085e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X1309.Fresh fruit intake,48597,0.0418465224364511,0.0146199463370612,0.0131914276158112,0.0705016172570909,0.00420771933282353
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X1319.Dried fruit intake,45888,-0.0336305939916547,0.015100579585131,-0.0632277299785115,-0.00403345800479798,0.0259450124308116
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X134.Number of self-reported cancers,50561,-0.0119317220945532,0.02619588009991,-0.0632756470903767,0.0394122029012704,0.648765288190262
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X135.Number of self-reported non-cancer illnesses,50562,0.0989095477656393,0.0139185078850925,0.071629272310858,0.12618982322042,1.20738290982075e-12
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X136.Number of operations, self-reported",50562,0.0214338759535446,0.0137373402485023,-0.00549131093351991,0.0483590628406091,0.118703793106722
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X137.Number of treatments or medications taken,50562,0.129091082246069,0.0137089248109222,0.102221589616661,0.155960574875476,4.8493542328339e-21
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X1438.Bread intake,49087,0.00709242310364241,0.00293765783676499,0.00133461374358304,0.0128502324637018,0.01576858311965
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X1458.Cereal intake,47994,0.0778549341115116,0.0138562037510691,0.0506967747594162,0.105013093463607,1.93376375065067e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X1488.Tea intake,48793,0.0083245063126741,0.00281678692502318,0.00280360393962865,0.0138454086857195,0.00312494345995608
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X1498.Coffee intake,46588,-0.00431941007187186,0.013968365258153,-0.0316974059778517,0.023058585834108,0.757149456494587
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X1528.Water intake,46752,-0.0839883539235546,0.0141395954866469,-0.111701961077382,-0.0562747467697268,2.87136876620173e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1568.Average weekly red wine intake,34416,-0.159154592397663,0.0163073257715518,-0.191116950909904,-0.127192233885421,1.79303358670836e-22
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1578.Average weekly champagne plus white wine intake,34408,-0.111942246535714,0.0166977367387513,-0.144669810543666,-0.0792146825277612,2.05868020430907e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1588.Average weekly beer plus cider intake,34499,-0.045298913746869,0.0184031666679061,-0.0813691204159648,-0.00922870707777312,0.0138416070217695
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1598.Average weekly spirits intake,34359,-0.014478092563404,0.0179011816476963,-0.0495644085928887,0.0206082234660807,0.418648112371571
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1608.Average weekly fortified wine intake,34472,0.0453841057134423,0.0292029089548565,-0.0118535958380766,0.102621807264961,0.120170852667607
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1737.Childhood sunburn occasions,37925,-0.0555933813270912,0.0165367026695108,-0.0880053185593325,-0.02318144409485,0.000775076948246299
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X1807.Father's age at death,37227,-0.0114809103132988,0.00326746246670883,-0.0178851367480481,-0.00507668387854946,0.000442421877856385
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X1845.Mother's age,19231,-0.000780994189024521,0.00736156411096377,-0.0152096598465135,0.0136476714684645,0.915511421801864
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X1873.Number of full brothers,49651,0.039639124939014,0.0134085152116957,0.0133584351240904,0.0659198147539377,0.0031153580785896
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X1883.Number of full sisters,49658,0.0210603421426419,0.0135195199622229,-0.00543791698331492,0.0475586012685988,0.119293461203774
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X20015.Sitting height,50173,-0.0112232582947771,0.00369527446013876,-0.0184659962366491,-0.00398052035290518,0.00238915881800729
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Cognitive function,X20016.Fluid intelligence score,16203,-0.0581946682052787,0.0223202557224586,-0.101942369421298,-0.0144469669892599,0.0091354298320469
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Cognitive function,X20018.Prospective memory result,16886,0.0483027588223357,0.0296830407648971,-0.00987600107686257,0.106481518721534,0.103695314855931
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X20019.Speech-reception-threshold (SRT) estimate (left),15998,0.00928913738051398,0.00508471357591899,-0.00067690122828724,0.0192551759893152,0.0677371673850328
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X20021.Speech-reception-threshold (SRT) estimate (right),15976,0.0104109860932202,0.00507704930013122,0.000459969464963029,0.0203620027214774,0.04032242486242
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Cognitive function,X20023.Mean time to correctly identify matches,49954,0.00812139879855279,0.00298088589441509,0.00227886244549922,0.0139639351516064,0.00644229599300237
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#1.Illnesses of father_Heart disease,43948,0.0168757854112568,0.00636392729224942,0.00440248791844798,0.0293490829040657,0.00800955606236133
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#10.Illnesses of father_Alzheimer's disease or dementia,43080,0.00695557086201422,0.0140041047810518,-0.0204924745088472,0.0344036162328757,0.61941665413064
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#11.Illnesses of father_Parkinson's disease,43012,0.0148158101886899,0.0187379229697465,-0.0219105188320132,0.0515421392093929,0.429131707469445
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#12.Illnesses of father_Severe depression,43049,-0.0103953103317776,0.015851647441188,-0.0414645393165061,0.0206739186529509,0.51196444377958
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#13.Illnesses of father_Prostate cancer,43076,-0.00195721929218033,0.0113304849743926,-0.0241649698419898,0.0202505312576291,0.862857215107003
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#2.Illnesses of father_Stroke,43406,0.00044436395349753,0.00817832189147685,-0.0155851469537971,0.0164738748607922,0.956669018203759
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#3.Illnesses of father_Lung cancer,43290,-0.00301366623085806,0.0103366599274149,-0.0232735196885913,0.0172461872268752,0.770631142910878
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#4.Illnesses of father_Bowel cancer,43099,-0.00610476251494316,0.012930328545721,-0.0314482064645564,0.0192386814346701,0.636838240644455
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#6.Illnesses of father_Chronic bronchitis or emphysema,43373,0.00790313039572931,0.00945872907883794,-0.0106359785987931,0.0264422393902517,0.403419297006089
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#8.Illnesses of father_High blood pressure,43512,0.00808091527330885,0.00712861663685214,-0.00589117333492134,0.022053003881539,0.256973597888466
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#9.Illnesses of father_Diabetes,43248,0.0167008744977312,0.00987807030361883,-0.00266014329736171,0.0360618922928241,0.0909009156059419
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#1.Illnesses of mother_Heart disease,46100,0.0259062450769467,0.00727154188611222,0.0116540229801667,0.0401584671737266,0.000367445192722028
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#10.Illnesses of mother_Alzheimer's disease or dementia,45818,-0.000191866602268662,0.0104384939457778,-0.0206513147359931,0.0202675815314557,0.985335246143702
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#11.Illnesses of mother_Parkinson's disease,45673,0.00221552892030712,0.0227010459564451,-0.0422785211543253,0.0467095789949395,0.922253611848909
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#12.Illnesses of mother_Severe depression,45745,0.0444728845898316,0.011681284663275,0.0215775666498126,0.0673682025298506,0.000140737358808749
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#2.Illnesses of mother_Stroke,45981,0.00733694623475984,0.00828371104536934,-0.00889912741416406,0.0235730198836837,0.375779718731984
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#3.Illnesses of mother_Lung cancer,45772,-0.00572780118893247,0.014640979588783,-0.0344241211829471,0.0229685188050821,0.695638610680172
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#4.Illnesses of mother_Bowel cancer,45734,-0.00598253408338803,0.0131250499706705,-0.0317076320259023,0.0197425638591262,0.648528500298586
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#5.Illnesses of mother_Breast cancer,45774,0.00452479648264091,0.0106864791858447,-0.0164207027216147,0.0254702956868965,0.671995796612276
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#6.Illnesses of mother_Chronic bronchitis or emphysema,45819,0.00312974090249569,0.0122817455858771,-0.0209424804458234,0.0272019622508147,0.798856574076087
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#8.Illnesses of mother_High blood pressure,46175,0.0141619221906878,0.00630102627178404,0.00181191069799107,0.0265119336833845,0.0246090882367107
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#9.Illnesses of mother_Diabetes,45885,0.0541772496997949,0.00973178510194419,0.0351029508999843,0.0732515484996055,2.60547113581593e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#1.Illnesses of siblings_Heart disease,39531,0.0252065142070115,0.0101879010068747,0.00523822823353711,0.0451748001804858,0.0133590918906537
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#10.Illnesses of siblings_Alzheimer's disease or dementia,39245,0.0605170630163601,0.0405085991457068,-0.0188797913092252,0.139913917341945,0.135201626518217
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#11.Illnesses of siblings_Parkinson's disease,39236,0.0143177252279764,0.0410108444203376,-0.0660635298358853,0.0946989802918382,0.727000744546462
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#12.Illnesses of siblings_Severe depression,39354,0.00801677225034952,0.0119935586169301,-0.0154906026388335,0.0315241471395326,0.503867442970911
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#13.Illnesses of siblings_Prostate cancer,39267,0.0336652275711383,0.0236003481065977,-0.0125914547177932,0.0799219098600698,0.153740196998343
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#2.Illnesses of siblings_Stroke,39314,0.00363734874732517,0.0172557172847651,-0.0301838571308144,0.0374585546254647,0.833051506820898
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#3.Illnesses of siblings_Lung cancer,39265,0.0348933729028947,0.0203370796678233,-0.00496730324603893,0.0747540490518282,0.0862154443320043
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#4.Illnesses of siblings_Bowel cancer,39266,0.026547089727471,0.0198418831420563,-0.0123430012309593,0.0654371806859014,0.180926366527556
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#5.Illnesses of siblings_Breast cancer,39294,-0.0503846892277368,0.0149580691927063,-0.0797025048454411,-0.0210668736100324,0.000756797344061528
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#6.Illnesses of siblings_Chronic bronchitis or emphysema,39314,0.0415279703619146,0.0183996816375345,0.00546459435234703,0.0775913463714823,0.0240139194788687
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#8.Illnesses of siblings_High blood pressure,39665,0.00147180618249961,0.00760649119761769,-0.0134369165648311,0.0163805289298303,0.846573530682668
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#9.Illnesses of siblings_Diabetes,39454,0.0303099792121629,0.0107953201407265,0.00915115173633901,0.0514688066879867,0.00499217727114087
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20127.Neuroticism score,40209,0.0370050883826367,0.0140932220539616,0.00938237315687192,0.0646278036084016,0.00864944641191995
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Cognitive function,X20128.Number of fluid intelligence questions attempted within time limit,16203,0.00558510549273702,0.022698444862066,-0.0389038464369123,0.0500740574223863,0.805641426689286
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X20161.Pack years of smoking,15384,0.0504915876437426,0.0055182293329612,0.0396758581511387,0.0613073171363466,6.39778779283935e-20
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X20162.Pack years adult smoking as proportion of life span exposed to smoking,15384,0.0506416493970627,0.00544364504708017,0.0399721051047855,0.0613111936893398,1.5474317201741e-20
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Cognitive function,X20191.Fluid intelligence score,12487,0.000410606336206367,0.0256191916090479,-0.0498030092175275,0.0506242218899402,0.987212872985325
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Cognitive function,X20192.Number of fluid intelligence questions attempted within time limit,12488,0.0319214739770916,0.0261710441942552,-0.0193737726436485,0.0832167205978317,0.222592266150233
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Cognitive function,X20240.Maximum digits remembered correctly,11219,-0.0718994783451516,0.0276173231730912,-0.12602943176441,-0.0177695249258928,0.00924206979786712
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X20255.Spirometry QC measure,37622,0.036078979422791,0.0178997754603487,0.00099541952050753,0.0711625393250746,0.043847795774779
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X20261.avMSE,11071,-0.00254429696722375,0.00597433706819103,-0.0142539976208782,0.00916540368643066,0.670210128755057
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X20262.Myopia diagnosis,11071,0.0228057041914097,0.0339807375816967,-0.0437965414687158,0.0894079498515352,0.502147767893571
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X20280.Glucose-lactate,28843,0.0116312257944767,0.00367884984494036,0.00442068009839358,0.0188417714905598,0.00157041885359232
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X20281.Spectrometer-corrected alanine,28906,0.0165864981192392,0.0037049710567081,0.00932475484809129,0.0238482413903871,7.6051715703746e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20544#11.Mental health problems ever diagnosed by a professional_Depression,15769,0.00939235376966229,0.0199655937896596,-0.0297402100580706,0.0485249175973952,0.63805651198767
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20544#6.Mental health problems ever diagnosed by a professional_Panic attacks,15766,-0.00749279577092294,0.0390965973506762,-0.0841221265782484,0.0691365350364025,0.848020188968347
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20546#1.Substances taken for depression_Unprescribed medication (more than once),15764,0.0262307500270794,0.0488740663724242,-0.0695624200628721,0.122023920117031,0.591481891064514
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20546#3.Substances taken for depression_Medication prescribed to you (for at least two weeks),15764,-0.0137577894075227,0.0189400654594214,-0.0508803177079887,0.0233647388929433,0.467613256496735
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20546#4.Substances taken for depression_Drugs or alcohol (more than once),15764,-0.0122426379921331,0.0329474594543337,-0.0768196585226271,0.052334382538361,0.71021010589383
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20548#1.Manifestations of mania or irritability_I was more talkative than usual,15775,0.0091293958426467,0.0425291238784686,-0.0742276869591517,0.0924864786444451,0.830033462728725
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20548#2.Manifestations of mania or irritability_I was more restless than usual,15775,-0.0224569846965505,0.027353346843203,-0.0760695445092284,0.0311555751161273,0.41166104002266
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20548#3.Manifestations of mania or irritability_My thoughts were racing,15775,0.0314331726334527,0.0306956998502756,-0.0287303990730876,0.0915967443399929,0.3058390511128
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20548#5.Manifestations of mania or irritability_I needed less sleep than usual,15775,-0.0523869603993617,0.0474247386634798,-0.145339448179782,0.0405655273810586,0.269335243294501
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20548#6.Manifestations of mania or irritability_I was more creative or had more ideas than usual,15775,0.0411029233752488,0.0548002242484127,-0.0663055161516401,0.148511362902138,0.453235620709879
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20548#7.Manifestations of mania or irritability_I was easily distracted,15775,0.0057296303544492,0.0318399972719506,-0.0566767642985739,0.0681360250074723,0.857193571655053
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20548#8.Manifestations of mania or irritability_I was more confident than usual,15775,0.015128374990472,0.054814349675804,-0.0923077503741039,0.122564500355048,0.782557086725459
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20548#9.Manifestations of mania or irritability_I was more active than usual,15775,0.00947933095151234,0.0409832262418246,-0.0708477924824638,0.0898064543854885,0.817086441412997
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20549#1.Substances taken for anxiety_Unprescribed medication (more than once),15776,0.0983576921183717,0.0558411975977546,-0.0110910551732274,0.207806439409971,0.0781931192214456
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20549#3.Substances taken for anxiety_Medication prescribed to you (for at least two weeks),15776,-0.0261246084618797,0.0254598744340892,-0.0760259623526944,0.0237767454289351,0.304855915074065
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20549#4.Substances taken for anxiety_Drugs or alcohol (more than once),15776,-0.0655850195311894,0.0378593111723387,-0.139789269428973,0.00861923036659447,0.0832334500329869
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20553#4.Methods of self-harm used_Ingesting a medication in excess of the normal dose,15778,0.0371032772487767,0.0631153753707791,-0.0866028584779503,0.160809412975504,0.556631787683855
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20600.Liking for adding salt to foods,18290,-0.0102841736181216,0.021273659809162,-0.0519805468440791,0.031412199607836,0.628801309182171
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20601.Liking for aniseed,18290,-0.0133980108309099,0.0209978224412325,-0.0545537428157255,0.0277577211539057,0.523438274308217
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20602.Liking for apple juice,18290,0.0927767786201492,0.0212475664355252,0.0511315484065198,0.134422008833779,1.2696720196689e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20603.Liking for apples,18290,0.00360280058252857,0.0217489497415776,-0.0390251409109636,0.0462307420760207,0.868431079417984
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20604.Liking for asparagus,18290,-0.114559033305207,0.0214930857135103,-0.156685481303687,-0.0724325853067264,9.93560421144285e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20605.Liking for aubergine,18290,-0.134361035970285,0.0213404101406841,-0.176188239846025,-0.0925338320945438,3.1221791710326e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20606.Liking for avocados,18290,-0.130175163694261,0.0215252919184211,-0.172364735854367,-0.0879855915341558,1.49931488408015e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20607.Liking for bacon,18290,0.0266729493040353,0.0214124660291116,-0.0152954841130235,0.0686413827210941,0.212900129395488
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20608.Liking for baked or steamed fish,18290,-0.0197823535390653,0.0215790700893634,-0.0620773309142175,0.022512623836087,0.35929205130328
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20609.Liking for bananas,18290,0.0839618164364459,0.0221325167427775,0.0405820836206021,0.12734154925229,0.00014896007230266
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20610.Liking for barbequed or grilled meat,18290,-0.057976583852514,0.0213094182533491,-0.0997430436290782,-0.0162101240759499,0.00652050537688303
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20611.Liking for beef steak,18290,-0.0287331984584128,0.0214191268520078,-0.070714687088348,0.0132482901715225,0.179783332670888
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20612.Liking for beetroot,18290,0.00786197519838778,0.0216101326704035,-0.0344938848356031,0.0502178352323786,0.71600435287549
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20613.Liking for bell pepper,18290,-0.0547126584451483,0.0214756776962465,-0.0968049867297914,-0.0126203301605052,0.0108530267650465
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20614.Liking for bicycling,18290,-0.0825174756239272,0.0213665005464315,-0.124395816694933,-0.0406391345529215,0.000112849259227616
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20615.Liking for biscuits,18290,0.153237453342349,0.0215045045094989,0.111088624503731,0.195386282180967,1.07311364532736e-12
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20616.Liking for bitter foods,18290,-0.109181652686159,0.0213174030931073,-0.150963762748649,-0.0673995426236682,3.05848270896046e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20617.Liking for bitter or ale,18290,-0.111157084506748,0.0218037458959306,-0.153892426462772,-0.0684217425507243,3.46555308792819e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20618.Liking for black olives,18290,-0.130881133085329,0.0214004049659152,-0.172825926818523,-0.088936339352135,9.80121117195638e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20619.Liking for black pepper,18290,-0.0870387324086723,0.0214344182425424,-0.129050192164055,-0.0450272726532893,4.91299020354356e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20620.Liking for blue cheese,18290,-0.0715104416447043,0.0213422094161669,-0.113341172100392,-0.0296797111890171,0.000807831631392895
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20621.Liking for bolognese sauce,18290,-0.00194849587159217,0.0213300277947557,-0.0437553503493133,0.039858358606129,0.927215572166919
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20622.Liking for broad beans,18290,-0.0701302074883771,0.0212979267891314,-0.111874143995075,-0.0283862709816796,0.000993768553658058
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20623.Liking for broccoli,18290,-0.0496776065957238,0.0219128053539334,-0.0926267050894332,-0.00672850810201446,0.0233983023442913
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20624.Liking for brown rice,18290,-0.000241434996018322,0.0213408146446651,-0.042069431699562,0.0415865617075254,0.990973610277355
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20625.Liking for brussel sprouts,18290,-0.00778448515006224,0.0215662320340179,-0.0500542999367374,0.0344853296366129,0.718135671379784
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20626.Liking for burgers (meat),18290,-0.0184163330055234,0.0213179425521337,-0.0601995004077054,0.0233668343966586,0.387660292167063
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20627.Liking for burn of spicy foods,18290,-0.0969026947956756,0.0213584817603547,-0.138765319045971,-0.0550400705453805,5.74328519518087e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20628.Liking for butter on bread,18290,0.0663048540520413,0.0217062050944741,0.023760692066872,0.10884901603721,0.00225648059835112
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20629.Liking for butternut squash,18290,-0.074633851547696,0.0212203378801058,-0.116225713792703,-0.0330419893026887,0.000437363464544987
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20630.Liking for cabbage,18290,-0.029894543160432,0.0216213857268252,-0.0722724591850095,0.0124833728641455,0.166792883640555
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20631.Liking for cake,18290,0.156634006136956,0.0214346546221695,0.114622083077504,0.198645929196409,2.83351618265399e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20632.Liking for cake icing,18290,0.157198840388128,0.0211921691500108,0.115662188854106,0.198735491922149,1.24313665169141e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20633.Liking for capers,18290,-0.139683493101248,0.0213829912976508,-0.181594156044643,-0.0977728301578519,6.64057016705879e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20634.Liking for cauliflower,18290,-0.0182921035044976,0.0216134534846391,-0.0606544723343902,0.0240702653253949,0.397380036200285
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20635.Liking for cereal or granola bar,18290,0.0700477032502763,0.0212417771339581,0.0284138200677184,0.111681586432834,0.000976877332475237
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20636.Liking for cheesecake,18290,0.141943550235744,0.0212687774699249,0.100256746394692,0.183630354076797,2.56422566432141e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20637.Liking for cherries,18290,0.0111915039459394,0.02241121837452,-0.0327344840681198,0.0551174919599986,0.617524329207238
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20638.Liking for chicken,18290,0.0236442354122971,0.0223315148575151,-0.0201255337084324,0.0674140045330266,0.289712472505188
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20639.Liking for chilli pepper,18290,-0.138801212458837,0.0212689503913946,-0.180488355225971,-0.0971140696917035,6.93234003923864e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20640.Liking for chips or french fries,18290,0.0412164604493945,0.0214759876542553,-0.000876475352945959,0.0833093962517349,0.0549760922816951
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20641.Liking for cigarette smoking,18290,0.040809770027439,0.0346194123152267,-0.0270442781104053,0.108663818165283,0.238488498583686
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20642.Liking for cod,18290,0.00355235196679058,0.0219275109922748,-0.039425569578068,0.0465302735116492,0.871304227248928
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20643.Liking for coffee with sugar,18290,0.109224477189784,0.023191004478499,0.0637701084119263,0.154678845967642,2.49810307869135e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20644.Liking for coffee without sugar,18290,-0.0935955489632943,0.0215802452324599,-0.135892829618916,-0.0512982683076729,1.45152647454732e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20645.Liking for coriander,18290,-0.110147610430145,0.0212413155271811,-0.15178058886342,-0.0685146319968704,2.1769196630596e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20646.Liking for corn flakes,18290,0.174979588783026,0.0212015914050569,0.133424469629114,0.216534707936937,1.64686099459944e-16
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20647.Liking for cream,18290,0.0729436945813828,0.0211976257863362,0.0313963480401639,0.114491041122602,0.000580595098030781
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20648.Liking for croissant,18290,0.049598511162171,0.0212628643301066,0.007923297075162,0.09127372524918,0.0196780890728918
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20649.Liking for cucumber,18290,-0.0249221211197329,0.021378326028318,-0.0668236401352361,0.0169793978957703,0.243724373419101
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20650.Liking for curry,18290,-0.0631846744879439,0.0215624043081814,-0.105446986931979,-0.0209223620439084,0.00339035776700287
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20651.Liking for dairy products,18290,0.0855038938826146,0.021746514846389,0.0428807247836921,0.128127062981537,8.4607967422914e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20652.Liking for dark chocolate,18290,-0.0137108144653262,0.0215577528690963,-0.055964010088755,0.0285423811581026,0.524781861299266
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20653.Liking for diet fizzy drinks,18290,0.122603717827479,0.0219285632487886,0.0796237338598532,0.165583701795104,2.28927458925216e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20654.Liking for dried fruit,18290,0.0508691503209599,0.0214524554018962,0.00882233773324342,0.0929159629086764,0.0177383116252773
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20655.Liking for eggs,18290,0.0237778118465053,0.021959287592492,-0.0192623918347789,0.0668180155277896,0.278905529309615
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20656.Liking for exercising alone,18290,-0.0855605063539471,0.0212674370527023,-0.127244682977244,-0.0438763297306507,5.76742563926707e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20657.Liking for exercising with others,18290,-0.0635656705319565,0.0212228540035533,-0.105162464378921,-0.0219688766849921,0.00274675953261294
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20658.Liking for extra virgin olive oil,18290,-0.119504279857136,0.0216099710139503,-0.161859823044478,-0.0771487366697933,3.24521525950017e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20659.Liking for fatty foods,18290,0.024270463993309,0.0212534934004262,-0.0173863830715263,0.0659273110581442,0.253489044292754
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20660.Liking for fresh tomatoes,18290,-0.0388455159283427,0.0227653852261402,-0.0834656709715774,0.00577463911489203,0.0879615593172565
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20661.Liking for fried chicken,18290,0.0339180411486129,0.0212998897131786,-0.00782974268921716,0.075665824986443,0.111311138750524
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20662.Liking for fried or battered fish,18290,0.0484590962081172,0.0214371592167775,0.00644226414323333,0.090475928273001,0.0238008047447623
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20663.Liking for fruit,18290,0.0240887139340935,0.0236857899677333,-0.0223354344026638,0.0705128622708508,0.309161565809413
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20664.Liking for garlic,18290,-0.111762369539173,0.021631673468857,-0.154160449538133,-0.0693642895402134,2.4088800771155e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20665.Liking for gherkins,18290,-0.101220386024495,0.0212779496800784,-0.142925167397449,-0.0595156046515416,1.9793817155973e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20666.Liking for globe artichoke,18290,-0.154118411675861,0.0215158685253026,-0.196289513985454,-0.111947309366268,8.19275333996109e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20667.Liking for goat's cheese,18290,-0.0923724272251857,0.0212512898510159,-0.134024955333177,-0.0507198991171945,1.38964385384852e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20668.Liking for going to a cafe,18290,0.0542245520528674,0.0214654141690731,0.0121523402814842,0.0962967638242506,0.0115408666211485
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20669.Liking for going to the gym,18290,-0.0428781741326638,0.021096242028874,-0.0842268085092569,-0.00152953975607074,0.0421172004974293
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20670.Liking for going to the pub,18290,-0.0974502575659797,0.0212659934087474,-0.139131604647124,-0.0557689104848349,4.62610090421678e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20671.Liking for grapefruit,18290,-0.0446919524919002,0.021227688106736,-0.0862982211811027,-0.00308568380269762,0.0352734879147896
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20672.Liking for green olives,18290,-0.112069904900895,0.0213776248891313,-0.153970049683593,-0.070169760118198,1.60271615353149e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20673.Liking for haddock,18290,-0.0252689221833731,0.0218452470787408,-0.068085606457705,0.0175477620909588,0.247400256196547
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20674.Liking for ham,18290,0.0702012377680513,0.0213568729581589,0.0283417667700599,0.112060708766043,0.00101431722608355
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20675.Liking for hard cheese,18290,-0.00980066008028414,0.0217277705274682,-0.0523870903141218,0.0327857701535535,0.651947284772852
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20676.Liking for herring,18290,-0.0427415307358023,0.0211185378862286,-0.0841338649928103,-0.00134919647879425,0.0429963246193909
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20677.Liking for honey,18290,0.0600307939862592,0.0212654618027653,0.0183504888528391,0.101711099119679,0.00476392153264311
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20678.Liking for horseradish or wasabi,18290,-0.0968305718622595,0.0213079121652057,-0.138594079706063,-0.0550670640184564,5.54586109972133e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20679.Liking for ice cream,18290,0.126632972817094,0.0214865313557029,0.0845193713599159,0.168746574274271,3.84520382145908e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20680.Liking for jam,18290,0.127824570633834,0.0212273283753074,0.0862190070182316,0.169430134249437,1.75898357716386e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20681.Liking for kiwi fruit,18290,0.00173542994530344,0.021364837169181,-0.0401396509062914,0.0436105107968983,0.935261263442333
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20682.Liking for lager,18290,-0.0907287866756439,0.0214630364923843,-0.132796338200717,-0.0486612351505706,2.37755188690538e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20683.Liking for lamb,18290,0.00326175157768481,0.0216469907689402,-0.039166350329438,0.0456898534848076,0.880230433716092
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20684.Liking for lemons,18290,-0.0885928131002324,0.0213747393298084,-0.130487302186657,-0.046698324013808,3.41727548193544e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20685.Liking for lentils or beans,18290,-0.0523962143576892,0.0214322252711411,-0.0944033758891258,-0.0103890528262526,0.0145050499527107
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20686.Liking for liver,18290,0.0197521878258045,0.0213081818936736,-0.0220118486857957,0.0615162243374046,0.353950886452756
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20687.Liking for mackerel,18290,-0.0533525119520318,0.0212667871392663,-0.0950354147449938,-0.0116696091590698,0.012125381679617
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20688.Liking for marzipan,18290,0.0878476913793394,0.0212129184066785,0.0462703713022495,0.129425011456429,3.46991995574524e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20689.Liking for mayonnaise,18290,-0.0422419159022449,0.021261990877981,-0.0839154180230877,-0.000568413781402037,0.0469668188293032
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20690.Liking for melon,18290,0.0327411547604823,0.0220315168858657,-0.0104406183358144,0.0759229278567791,0.137268519593016
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20691.Liking for milk chocolate,18290,0.162783430399562,0.0214273750829681,0.120785775236945,0.20478108556218,3.17715632880757e-14
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20692.Liking for mushrooms,18290,-0.00183247178907133,0.022005802603664,-0.0449638448922528,0.0412989013141101,0.933636010139785
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20694.Liking for orange juice,18290,0.0758657834711368,0.0212444879220463,0.034226587143926,0.117504979798348,0.000356424351814588
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20695.Liking for oranges,18290,0.00260996306570331,0.0217102983011466,-0.0399422216045441,0.0451621477359507,0.904311984800284
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20696.Liking for pasta,18290,-0.00136546278900141,0.0216048584042014,-0.0437109852612361,0.0409800596832333,0.949606619103181
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20697.Liking for pears,18290,0.0311543411706398,0.0218088894529045,-0.0115910821570531,0.0738997644983326,0.153160574145552
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20698.Liking for pizza,18290,-0.000849083699960635,0.021363413619339,-0.0427213743938652,0.0410232069939439,0.968297052630563
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20699.Liking for plain yogurt,18290,-0.0589496245948194,0.0213045087581554,-0.100706461760804,-0.0171927874288347,0.00566312571506492
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20700.Liking for plums,18290,0.0335757838245092,0.0217541405824397,-0.00906233171707264,0.076213899366091,0.122746135556925
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20701.Liking for pollock,18290,-0.0101142785436597,0.0212047664016693,-0.0516756206909315,0.0314470636036121,0.633381093382232
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20702.Liking for pork chop,18290,0.0229417276493656,0.021267236210284,-0.0187420553227911,0.0646255106215222,0.28071979511791
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20703.Liking for porridge,18290,0.0320455429860135,0.0216771631319256,-0.0104416967525607,0.0745327827245877,0.139342360870887
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20704.Liking for potato crisps,18290,0.048581401125224,0.0212635032892358,0.00690493467832179,0.0902578675721263,0.0223399736376303
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20705.Liking for potatoes,18290,0.0597384953594173,0.0216852183069251,0.017235467477844,0.102241523240991,0.00587856894509294
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20706.Liking for prawns,18290,-0.0857765006153023,0.0215711723109681,-0.1280559983448,-0.0434970028858047,7.02236366227688e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20707.Liking for raw carrots,18290,-0.0283435887594343,0.0216227132263621,-0.0707241066831039,0.0140369291642354,0.189933440359673
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20708.Liking for red meat,18290,-0.0368449006946275,0.0213275816122206,-0.0786469606545798,0.00495715926532479,0.0840821589542427
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20709.Liking for red wine,18290,-0.189595402527042,0.0214504707339288,-0.231638325165542,-0.147552479888542,1.05423979637937e-18
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20710.Liking for regular (non-diet) fizzy drinks,18290,0.139700358320964,0.0219917861711604,0.0965964574254899,0.182804259216439,2.17005001435408e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20711.Liking for roast chicken,18290,0.0377680128803636,0.0224142232483657,-0.00616386468643314,0.0816998904471603,0.0920052509225408
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20712.Liking for salad dressing,18290,-0.0249033074357,0.0212387702140958,-0.0665312970553279,0.0167246821839278,0.240995616715015
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20713.Liking for salad leaves,18290,-0.0701917312419707,0.0217097233492375,-0.112742789006476,-0.0276406734774653,0.00122632014525703
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20714.Liking for salami,18290,-0.0818606327824252,0.0214510928636917,-0.123904774795261,-0.0398164907695895,0.000135995765010258
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20715.Liking for salmon,18290,-0.0487812059802697,0.0222746950678895,-0.0924396083133331,-0.0051228036472063,0.0285380615919474
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20716.Liking for salty foods,18290,0.0100726100514491,0.0211588214477486,-0.0313986799861382,0.0515439000890364,0.634046029342411
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20717.Liking for salty pretzels,18290,-0.0418845210907601,0.0213334843177115,-0.0836981503534747,-7.08918280455453e-05,0.0496237986993234
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20718.Liking for sardines,18290,-0.0568991091791935,0.0212311942951767,-0.0985122499977399,-0.0152859683606471,0.00736932748472127
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20719.Liking for sausages (meat),18290,0.0181330870824511,0.0213913506105757,-0.0237939601142772,0.0600601342791794,0.396625569266557
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20720.Liking for savoury biscuits,18290,0.0399097156979526,0.021428882348534,-0.00209089370517405,0.0819103251010793,0.0625590564789802
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20721.Liking for shellfish (other than prawns),18290,-0.131374915919827,0.0211110777670733,-0.172752628343291,-0.0899972034963636,4.98256755133034e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20722.Liking for skimmed milk,18290,0.0504690882991459,0.0212251739201613,0.0088677474156298,0.0920704291826619,0.0174267868630711
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20723.Liking for smoked fish,18290,-0.043015966601289,0.0212859234303362,-0.084736376524748,-0.00129555667783002,0.0433083553748427
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20724.Liking for soft cheese,18290,0.0280027298970445,0.0212184464330776,-0.0135854251117876,0.0695908849058766,0.186939994053585
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20725.Liking for soy sauce,18290,-0.0243523357326221,0.0213812622281226,-0.0662596096997425,0.0175549382344982,0.254736075097805
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20726.Liking for soya milk,18290,-0.0340901358066629,0.0215059928916883,-0.0762418818743719,0.00806161026104608,0.112950505727856
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20727.Liking for spicy foods,18290,-0.116650267337072,0.0214615843087167,-0.158714972582156,-0.0745855620919869,5.54033794677948e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20728.Liking for spinach,18290,-0.0991419112963107,0.0214537289508633,-0.141191220040003,-0.0570926025526188,3.8413943787332e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20729.Liking for spirits,18290,-0.072304266409511,0.0213775313844507,-0.114204227923034,-0.0304043048959877,0.000720441320461974
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20730.Liking for strawberries,18290,0.0615486898373807,0.023452603375709,0.0155815872209911,0.10751579245377,0.00868775045408081
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20731.Liking for sweet coffee house drinks,18290,0.132956063369194,0.0217690387986985,0.0902887473237453,0.175623379414643,1.0320172267676e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20732.Liking for sweet foods,18290,0.226623945158808,0.0213716052685646,0.184735598832421,0.268512291485195,3.40330158069429e-26
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20733.Liking for taking the stairs,18290,-0.0768378475144152,0.0218030192181922,-0.119571765182072,-0.0341039298467585,0.000425827977579399
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20734.Liking for tea with sugar,18290,0.122246887169413,0.0254424038294969,0.0723797756635989,0.172113998675227,1.56098816605396e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20735.Liking for tea without sugar,18290,-0.0339491735542835,0.0221624610847842,-0.0773875972804604,0.00948925017189353,0.125581142280569
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20736.Liking for tomato ketchup,18290,0.0705728866475706,0.0213422370184006,0.0287421020915054,0.112403671203636,0.000945759468882122
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20737.Liking for tinned tuna,18290,0.00140167041424778,0.0214160176331532,-0.0405737241467325,0.0433770649752281,0.947816726536446
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20738.Liking for turnip (white),18290,0.0154491971511961,0.0212489262655443,-0.0261986983292708,0.0570970926316629,0.467199878360956
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20739.Liking for vegetables,18290,-0.0553980161592561,0.0234707089240009,-0.101400605650298,-0.00939542666821427,0.0182703979312538
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20740.Liking for vinegar,18290,0.00322824546809245,0.0213405601651857,-0.0385992524556714,0.0450557433918563,0.879762225597908
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20741.Liking for watching television,18290,0.0624316328320475,0.0215150822663591,0.0202620715899836,0.104601194074111,0.00371514422811858
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20742.Liking for whisky,18290,-0.101088499503485,0.0223275303367949,-0.144850458963603,-0.057326540043367,6.00549372475812e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20743.Liking for white bread,18290,0.0862848210856438,0.0212196802671061,0.0446942477621158,0.127875394409172,4.79730562062193e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20744.Liking for white rice,18290,0.0203511253194844,0.0214015893374055,-0.0215959897818305,0.0622982404207992,0.341659325020143
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20745.Liking for white wine,18290,-0.165066960863346,0.021185152218986,-0.206589859212558,-0.123544062514133,6.96769752971726e-15
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20746.Liking for whole grain breakfast cereal,18290,0.0399334265142964,0.0214614559692554,-0.0021310271854443,0.081997880214037,0.0628019817064488
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20747.Liking for whole milk,18290,0.0808237795155212,0.0212299486168259,0.0392130802265424,0.1224344788045,0.000141085567335063
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20748.Liking for wholemeal bread,18290,0.0128002200173692,0.0222869017995817,-0.0308821075098111,0.0564825475445494,0.565746007272712
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20749.Liking for working up a sweat,18290,-0.105983334838587,0.0213872227098975,-0.147902291349986,-0.0640643783271882,7.28083136840509e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X21001.Body mass index (BMI),50328,0.105322780379301,0.0122694235702079,0.0812747101816936,0.129370850576908,9.40651258255205e-18
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X21002.Weight,50367,-0.0108159483072767,0.00690260113215313,-0.0243450465262968,0.00271314991174347,0.117135458279564
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X21021.Pulse wave Arterial Stiffness index,16763,0.0153320289627202,0.00502337653110131,0.00548621096176167,0.0251778469636788,0.00227574936139166
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21025.Frequency of discomfort or pain in abdomen in last 3 months,17460,0.0392754861416035,0.0228068045850404,-0.00542585084507577,0.0839768231282828,0.0850700245287429
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21033.Frequency of hard or lumpy stools in the last 3 months,17476,-0.0474422241940562,0.0235147790421235,-0.0935311911166184,-0.00135325727149412,0.0436535000367525
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21034.Frequency of loose or mushy or watery stools in the last 3 months,17478,-0.0357490056588443,0.023188666594341,-0.0811987921837526,0.00970078086606408,0.123174715737297
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21040.Satisfaction with bowel habits,17405,0.0428913973008431,0.0216301040286032,0.000496393404780818,0.0852864011969054,0.0473888192983165
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21041.Degree to which abdominal pain or discomfort or altered bowel habits affect or interfere with life in general,17385,0.0508774165323521,0.022883729160088,0.00602530737857963,0.0957295256861245,0.026208335910646
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21042.Greatest number of times bowels opened per day,17396,0.010416147247273,0.0232526713018112,-0.0351590885042768,0.0559913829988229,0.654191353734307
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21043.Least number of times bowels opened per week,17272,-0.0502577696147109,0.0231279331998745,-0.0955885186864648,-0.00492702054295697,0.0297913664173674
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21044.Average number of times bowels opened per day,17335,-0.00246609049236637,0.0259416958801169,-0.0533118144173954,0.0483796334326627,0.924266038180357
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21048.Degree bothered by back pain in the past 3 months,17487,-0.0321183290312521,0.0235699439585217,-0.0783154191899545,0.0140787611274504,0.17300044112613
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21049.Degree bothered by pain in arms or legs or joints in the past 3 months,17477,-0.0149227721823914,0.0236910455615478,-0.0613572214830251,0.0315116771182422,0.528774259235768
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21050.Degree bothered by menstrual cramps or other problems with period in the last 3 months,9831,0.0518417697906348,0.0372351985813776,-0.0211392194288653,0.124822759010135,0.163869591369611
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21051.Degree bothered by headaches in the last 3 months,17482,-0.00939024424198668,0.0255674347330054,-0.0595024163186772,0.0407219278347038,0.713419380841331
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21052.Degree bothered by chest pain in the last 3 months,17480,-0.0670605484562457,0.035062649580828,-0.135783341634669,0.00166224472217726,0.0558166236067988
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21053.Degree bothered by dizziness in the last 3 months,17482,-0.0694319569706233,0.0275571315389354,-0.123443934786937,-0.0154199791543098,0.0117588730592198
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21054.Degree bothered by fainting spells in the last 3 months,17481,-0.000538725993355991,0.069009516478048,-0.13579737829033,0.134719926303618,0.993771429565295
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21055.Degree bothered by feeling heart pound or race in the last 3 months,17486,0.0336375159252906,0.0271532927449715,-0.0195829378548535,0.0868579697054348,0.215435986705909
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21056.Degree bothered by shortness of breath in the last 3 months,17484,-0.0924742946417211,0.0265836996187827,-0.144578345894535,-0.040370243388907,0.000505251024557709
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21057.Degree bothered by pain or problems during intercourse in the last 3 months,17084,0.0327051226693149,0.0243647142934486,-0.0150497173458444,0.0804599626844742,0.179511719467607
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21058.Degree bothered by urinary frequency or bladder irritability in the last 3 months,17478,-0.0183861278510023,0.0241066755229073,-0.0656352118759005,0.0288629561738959,0.445653463222173
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21059.Degree bothered by nausea in the last 3 months,17485,-0.089957819488903,0.0345075403861356,-0.157592598645729,-0.0223230403320772,0.00914427830978545
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21060.Degree bothered by feeling tired all the time in the last 3 months,17486,-0.119365376119008,0.0236620033211285,-0.16574290262842,-0.0729878496095959,4.5902354388462e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21061.Degree bothered by trouble sleeping in the last 3 months,17483,-0.0326744181309311,0.0235969624342751,-0.0789244645021103,0.0135756282402481,0.166165738889412
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X21100.Water hardness (USGS classification),50067,-0.0219537035383923,0.0134801963701072,-0.0483748884238023,0.00446748134701777,0.103406285079839
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X2139.Age first had sexual intercourse,43659,-0.00498634909624021,0.00314771120425851,-0.0111558630565869,0.00118316486410646,0.113173888740291
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2149.Lifetime number of sexual partners,40507,-0.0596822581822411,0.0154548367456897,-0.0899737382037929,-0.0293907781606893,0.000112766359231237
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X22032.IPAQ activity group,40510,-0.131352850361485,0.0151739537663593,-0.161093799743549,-0.10161190097942,5.042120724044e-18
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X22033.Summed days activity,41582,-0.0282571735390065,0.0030454561098738,-0.0342262675143591,-0.0222880795636538,1.79940412526459e-20
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X22034.Summed minutes activity,40510,-0.0253829915500284,0.00306561852731159,-0.0313916038635591,-0.0193743792364977,1.27018751890886e-16
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X22037.MET minutes per week for walking,38776,-0.0170178974305738,0.00312568101373431,-0.023144232217493,-0.0108915626436545,5.22539799946603e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X22038.MET minutes per week for moderate activity,40510,-0.0204271832379361,0.00307172499298351,-0.0264477642241837,-0.0144066022516884,2.96671728668398e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X22039.MET minutes per week for vigorous activity,40510,-0.149599495804614,0.0152552377053077,-0.179499761707017,-0.119699229902211,1.11963279803576e-22
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X22040.Summed MET minutes per week for all activity,38776,-0.0270831606117597,0.00313738623227436,-0.0332324376270174,-0.0209338835965019,6.23272587439548e-18
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X2217.Age started wearing glasses or contact lenses,42941,-0.00910657035182036,0.00305989393787303,-0.0151039624700515,-0.00310917823358923,0.00292096092147612
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X22501.Year ended full time education,12266,-0.0527306144762568,0.0139816316003611,-0.0801346124129644,-0.0253266165395491,0.000163084191975891
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X22506.Tobacco smoking,12184,-0.111186454757881,0.0553167928382318,-0.219607368720815,-0.00276554079494654,0.0444537908786605
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X2277.Frequency of solarium or sunlamp use,47260,0.0119469079536152,0.0355266198993759,-0.0576852670491616,0.0815790829563919,0.736660879665877
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23098.Weight,49513,-0.0103820965646931,0.00696676548595216,-0.0240369569171593,0.00327276378777318,0.136169628167379
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23099.Body fat percentage,49483,0.0570114055698268,0.00668511099070891,0.0439085880280373,0.0701142231116162,1.52887113728462e-17
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23100.Whole body fat mass,49435,0.0403425147532934,0.00645861464991328,0.0276836300394634,0.0530013994671234,4.2367278710379e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23101.Whole body fat-free mass,49507,-0.0373787483438462,0.00581751678337116,-0.0487810812392536,-0.0259764154484387,1.32883154540095e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23102.Whole body water mass,49513,-0.0379001235210746,0.00582595565553191,-0.0493189966059171,-0.026481250436232,7.82280181679764e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23104.Body mass index (BMI),49513,0.106431820814244,0.0123353022222909,0.0822546284585542,0.130609013169935,6.41237095854057e-18
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23105.Basal metabolic rate,49511,-0.0363263739200255,0.00622604845986602,-0.0485294289013629,-0.0241233189386881,5.4261287688978e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23106.Impedance of whole body,49507,0.0329305924300002,0.00476601366151773,0.0235892056534255,0.042271979206575,4.92358310572612e-12
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23107.Impedance of leg (right),49510,0.0302871587225644,0.00388552300504998,0.0226715336326664,0.0379027838124623,6.57257566216953e-15
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23108.Impedance of leg (left),49509,0.0269398333085554,0.00386016007607823,0.019373919559442,0.0345057470576687,3.01140674567377e-12
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23109.Impedance of arm (right),49500,0.0190777338037234,0.00475010105701635,0.00976753573197132,0.0283879318754754,5.92113163096095e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23110.Impedance of arm (left),49508,0.0170861262440758,0.00475527030171507,0.00776579645271428,0.0264064560354374,0.000327093303282662
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23111.Leg fat percentage (right),49509,0.0656222431844931,0.00807699370705058,0.049791335518674,0.0814531508503122,4.5916942172261e-16
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23112.Leg fat mass (right),49508,0.047429648179075,0.00859665820420806,0.0305801980988272,0.0642790982593228,3.461256692444e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23113.Leg fat-free mass (right),49507,-0.0447958928958987,0.00608822736012886,-0.0567288185217513,-0.0328629672700462,1.8987072560533e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23114.Leg predicted mass (right),49506,-0.0445997805871901,0.00611802641618366,-0.05659111236291,-0.0326084488114701,3.14813861236952e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23115.Leg fat percentage (left),49503,0.0611549008659606,0.00842378629262683,0.044644279732412,0.0776655219995092,3.93380370993555e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23116.Leg fat mass (left),49503,0.042209104627169,0.00897158538162897,0.0246247972791762,0.0597934119751617,2.54857615965824e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23117.Leg fat-free mass (left),49500,-0.0416596569511552,0.00635984235836759,-0.0541249479735556,-0.0291943659287547,5.79350552554717e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23118.Leg predicted mass (left),49499,-0.0415189482380779,0.00639144364861895,-0.054046177789371,-0.0289917186867848,8.32524630563527e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23119.Arm fat percentage (right),49499,0.0599752661851913,0.00743203140085973,0.0454084846395062,0.0745420477308764,7.19634008668795e-16
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23120.Arm fat mass (right),49494,0.0505603311400712,0.0073632589088229,0.0361283436787783,0.0649923186013641,6.65377779548978e-12
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23121.Arm fat-free mass (right),49495,-0.0292780995460584,0.00586121794957696,-0.0407660867272292,-0.0177901123648875,5.89670935138565e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23122.Arm predicted mass (right),49494,-0.0276156739006157,0.00586898546062655,-0.0391188854034437,-0.0161124623977876,2.54105794923652e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23123.Arm fat percentage (left),49489,0.0573297671968025,0.00761810457133398,0.0423982822369879,0.0722612521566171,5.34216371755835e-14
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23124.Arm fat mass (left),49488,0.0453383351781053,0.00734882835475785,0.03093463160278,0.0597420387534307,6.90511530956766e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23125.Arm fat-free mass (left),49484,-0.0259277476856584,0.0059752520160861,-0.0376392416371872,-0.0142162537341297,1.4329264019662e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23126.Arm predicted mass (left),49481,-0.0258268615763128,0.00599343173125701,-0.0375739877695765,-0.0140797353830491,1.64166344990976e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23127.Trunk fat percentage,49477,0.0358563667839235,0.00479122126716457,0.0264655731002809,0.0452471604675661,7.34183770216124e-14
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23128.Trunk fat mass,49474,0.0290600241881194,0.00527446842846776,0.0187220660683226,0.0393979823079162,3.61510575628688e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23129.Trunk fat-free mass,49467,-0.0314410673952594,0.00527155301677601,-0.0417733113081404,-0.0211088234823784,2.47364996790817e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23130.Trunk predicted mass,49462,-0.0312524800544273,0.00527429932072802,-0.0415901067230542,-0.0209148533858004,3.13541807852036e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23400.Total Cholesterol,28916,-0.0569652673801738,0.00372791202537771,-0.0642719749499141,-0.0496585598104334,1.64929740773679e-52
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23401.Total Cholesterol Minus HDL-C,28916,0.00467868651241171,0.0036275842781121,-0.00243137867268799,0.0117887516975114,0.197146865622737
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,"X23402.Remnant Cholesterol (Non-HDL, Non-LDL -Cholesterol)",28916,0.0231647731569127,0.00363050022043505,0.01604899272486,0.0302805535889654,1.7906386951834e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23403.VLDL Cholesterol,28916,0.0843443818326683,0.00360731588303496,0.0772740427019198,0.0914147209634168,8.55330220814204e-120
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23404.Clinical LDL Cholesterol,28916,-0.0161214467326787,0.00363102127759055,-0.0232382484367562,-0.00900464502860122,9.03251101430594e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23405.LDL Cholesterol,28916,-0.0123646661174112,0.0036214318983361,-0.01946267263815,-0.00526665959667249,0.000640331780990567
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23406.HDL Cholesterol,28916,-0.22817826464015,0.00399309578715829,-0.23600473238298,-0.220351796897319,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23407.Total Triglycerides,28916,0.129509251313117,0.00377827764079553,0.122103827137157,0.136914675489076,1.95352616635376e-252
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23408.Triglycerides in VLDL,28916,0.139615311428859,0.00379594926480359,0.132175250869844,0.147055371987874,1.8285145303045e-289
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23409.Triglycerides in LDL,28916,0.0807885565883546,0.0037062454562314,0.0735243154941411,0.0880527976825682,1.6882533521763e-104
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23410.Triglycerides in HDL,28916,0.0656337348647885,0.00369089702655247,0.0583995766927456,0.0728678930368313,2.28771896922612e-70
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23411.Total Phospholipids in Lipoprotein Particles,28916,-0.0661353158633356,0.00377713757339417,-0.0735385055071882,-0.058732126219483,2.73874112269198e-68
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23412.Phospholipids in VLDL,28916,0.114502385048592,0.00366384825912826,0.107321242460701,0.121683527636484,6.82838526833509e-211
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23413.Phospholipids in LDL,28916,-0.00242585388818976,0.00361440607713538,-0.00951008979937511,0.00465838202299559,0.502122366521987
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23414.Phospholipids in HDL,28916,-0.177937086677071,0.00392427439441883,-0.185628664490132,-0.17024550886401,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23415.Total Esterified Cholesterol,28916,-0.0688789710709308,0.00373991962034886,-0.0762092135268145,-0.061548728615047,2.58040527078808e-75
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23416.Cholesteryl Esters in VLDL,28916,0.0699198365441931,0.00359711699065065,0.0628694872425178,0.0769701858458684,1.26695828533974e-83
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23417.Cholesteryl Esters in LDL,28916,-0.00270660997694666,0.00361498813653459,-0.00979198672455444,0.00437876677066113,0.454032736607733
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23418.Cholesteryl Esters in HDL,28916,-0.233436210192736,0.00396861742979283,-0.24121470035513,-0.225657720030342,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23419.Total Free Cholesterol,28916,-0.0269450831582302,0.00369501109694947,-0.0341873049082511,-0.0197028614082092,3.12557421760134e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23420.Free Cholesterol in VLDL,28916,0.102445000883369,0.00364067119782195,0.0953092853356384,0.1095807164311,6.8015223765548e-172
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23421.Free Cholesterol in LDL,28916,-0.0381972747878816,0.00365032771079907,-0.0453519171010478,-0.0310426324747154,1.40345007671913e-25
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23422.Free Cholesterol in HDL,28916,-0.196277679510588,0.00404679365511813,-0.204209395074619,-0.188345963946556,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23423.Total Lipids in Lipoprotein Particles,28916,-0.0113976717431091,0.00366560232958165,-0.0185822523090892,-0.0042130911771291,0.00187676219469546
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23424.Total Lipids in VLDL,28916,0.123549963660577,0.00370231370497689,0.116293428798822,0.130806498522331,1.28339842777346e-239
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23425.Total Lipids in LDL,28916,-0.00445304340795182,0.00361701822932915,-0.0115423991374369,0.00263631232153331,0.218281808918641
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23426.Total Lipids in HDL,28916,-0.195507290217302,0.00395505046336097,-0.20325918912549,-0.187755391309115,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23427.Total Concentration of Lipoprotein Particles,28916,-0.155447977512888,0.00375518674678264,-0.162808143536582,-0.148087811489194,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23428.Concentration of VLDL Particles,28916,0.0943170880686693,0.00363055848998498,0.0872011934282988,0.10143298270904,4.22438038541945e-147
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23429.Concentration of LDL Particles,28916,0.0330381113407884,0.0036017131664372,0.0259787535345715,0.0400974691470053,4.90246476080482e-20
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23430.Concentration of HDL Particles,28916,-0.17018720150606,0.00374690622875313,-0.177531137714416,-0.162843265297703,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23431.Average Diameter for VLDL Particles,28916,0.150973233002594,0.00393601290519034,0.143258647708421,0.158687818296767,1.66880669405671e-308
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23432.Average Diameter for LDL Particles,28916,-0.0616072936260244,0.00375202660812436,-0.0689612657779482,-0.0542533214741007,2.59284984927913e-60
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23433.Average Diameter for HDL Particles,28916,-0.173785290771882,0.00419053355589103,-0.181998736541429,-0.165571845002336,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23434.Phosphoglycerides,28893,-0.0819312684552673,0.00379013084749126,-0.0893599249163502,-0.0745026119941845,8.13090562933175e-103
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23435.Triglycerides to Phosphoglycerides ratio,28893,0.199530128144624,0.00392305951236223,0.191840931500394,0.207219324788854,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23436.Total Cholines,28893,-0.093822804149316,0.00381551423006302,-0.101301212040239,-0.0863443962583924,3.72012967793702e-132
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23437.Phosphatidylcholines,28893,-0.0989169579615883,0.00382529388745073,-0.106414533980992,-0.0914193819421848,8.89771555642316e-146
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23438.Sphingomyelins,28892,-0.0927547149134952,0.00384464712180442,-0.100290223272232,-0.0852192065547586,2.45317925041675e-127
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23439.Apolipoprotein B,28916,0.0352144095350072,0.0036055115791729,0.0281476068398283,0.0422812122301861,1.69313870785775e-22
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23440.Apolipoprotein A1,28916,-0.185852724433495,0.00385669305800751,-0.19341184282719,-0.1782936060398,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23441.Apolipoprotein B to Apolipoprotein A1 ratio,28916,0.122914535027366,0.00361545807316982,0.115828237203954,0.130000832850779,1.94941524371304e-248
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23442.Total Fatty Acids,28893,0.0321198975152121,0.00367056020491475,0.0249255995135792,0.039314195516845,2.23387631031066e-18
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23443.Degree of Unsaturation,28893,-0.127546191594073,0.00390414510169248,-0.13519831599339,-0.119894067194756,6.54299625440981e-230
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23444.Omega-3 Fatty Acids,28893,-0.0220641217918341,0.00374672317052722,-0.0294076992060674,-0.0147205443776007,3.93045341449504e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23445.Omega-6 Fatty Acids,28893,-0.021301143052493,0.00367762406692157,-0.0285092862236592,-0.0140929998813267,7.02346961148587e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23446.Polyunsaturated Fatty Acids,28893,-0.0240548734806874,0.00369401656507249,-0.0312951459482294,-0.0168146010131453,7.54501012938253e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23447.Monounsaturated Fatty Acids,28893,0.0832432162113205,0.00373587293046192,0.0759209052676151,0.0905655271550258,4.58045032878761e-109
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23448.Saturated Fatty Acids,28893,0.0341640538251283,0.00368875086833716,0.0269341021231875,0.0413940055270692,2.1475261352434e-20
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23449.Linoleic Acid,28893,-0.00887774084421346,0.00366526873814545,-0.0160616675709785,-0.00169381411744838,0.0154361352202997
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23450.Docosahexaenoic Acid,28893,-0.0901872266089969,0.00381781919491812,-0.0976701522310364,-0.0827043009869573,3.25600376764375e-122
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23451.Omega-3 Fatty Acids to Total Fatty Acids percentage,28893,-0.0473011346804191,0.00377255221719726,-0.0546953370261257,-0.0399069323347124,5.72289575674694e-36
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23452.Omega-6 Fatty Acids to Total Fatty Acids percentage,28893,-0.108334635846473,0.00388195413976126,-0.115943265960405,-0.100726005732541,3.8396959944056e-169
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23453.Polyunsaturated Fatty Acids to Total Fatty Acids percentage,28893,-0.132304615055722,0.00393358827408614,-0.140014448072931,-0.124594782038513,2.61273923167801e-243
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23454.Monounsaturated Fatty Acids to Total Fatty Acids percentage,28893,0.171289992929403,0.00395408857435868,0.16353997932366,0.179040006535146,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23455.Saturated Fatty Acids to Total Fatty Acids percentage,28893,0.0243727558722758,0.00368762188429062,0.0171450169790662,0.0316004947654854,3.92748010739267e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23456.Linoleic Acid to Total Fatty Acids percentage,28893,-0.0751785020435613,0.00390472432712477,-0.0828317617247259,-0.0675252423623968,4.34256058164256e-82
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23457.Docosahexaenoic Acid to Total Fatty Acids percentage,28893,-0.112910811184067,0.00381877038428793,-0.120395601137271,-0.105426021230863,2.61752924526038e-189
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23458.Polyunsaturated Fatty Acids to Monounsaturated Fatty Acids ratio,28893,-0.163138290060771,0.00396840671261739,-0.170916367217501,-0.155360212904041,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23459.Omega-6 Fatty Acids to Omega-3 Fatty Acids ratio,28891,0.0153915563658316,0.00374278267589583,0.0080557023210758,0.0227274104105874,3.9276967060378e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23460.Alanine,28906,0.0141779168541526,0.00366533722855581,0.00699385588618323,0.021361977822122,0.00010992394770212
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23461.Glutamine,28822,-0.0551948257909843,0.00362350193008232,-0.0622968895739456,-0.0480927620080229,3.4412304942869e-52
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23462.Glycine,28881,-0.00400744768194726,0.00385058838335653,-0.0115546009133261,0.00353970554943155,0.298006598053839
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23463.Histidine,28879,-0.000937544541974764,0.00362080912319098,-0.00803433042342909,0.00615924133947956,0.79568929941344
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23464.Total Concentration of Branched-Chain Amino Acids (Leucine + Isoleucine + Valine),28897,0.0492976409656923,0.0038281229191244,0.0417945200442085,0.0568007618871762,7.63439562235306e-38
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23465.Isoleucine,28910,0.0561855321640757,0.00373201017106628,0.0488707922287858,0.0635002720993656,4.9979255587366e-51
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23466.Leucine,28911,0.0398364333420023,0.00382218662886156,0.0323449475494337,0.047327919134571,2.17310051858611e-25
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23467.Valine,28897,0.0473427369962474,0.00383474642170891,0.0398266340096979,0.0548588399827968,6.29285350143966e-35
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23468.Phenylalanine,28905,0.0311730720238177,0.00365125740908822,0.0240166075020048,0.0383295365456307,1.4362158545368e-17
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23469.Tyrosine,28883,0.0166248037688222,0.00371505661445529,0.0093432928044898,0.0239063147331545,7.67103331983233e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23470.Glucose,28861,0.00606440596664042,0.00367539249847615,-0.00113936333037282,0.0132681752636537,0.0989533588539126
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23471.Lactate,28862,0.00571330803976638,0.0036541256747074,-0.00144877828266012,0.0128753943621929,0.117940695479415
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23472.Pyruvate,28822,-0.0386434727691258,0.00362894650435229,-0.0457562079176562,-0.0315307376205953,1.9807215089551e-26
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23473.Citrate,28911,0.00764993033383266,0.003697054046401,0.000403704402886701,0.0148961562647786,0.0385365442814495
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23474.3-Hydroxybutyrate,28449,-0.000390592188343933,0.00370814800451063,-0.00765856227718477,0.00687737790049691,0.916111928813365
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23475.Acetate,28890,-0.0247601945088276,0.00363254039678598,-0.0318799736865281,-0.0176404153311271,9.53042941659575e-12
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23476.Acetoacetate,28914,0.0189674227244426,0.00364315771728629,0.0118268335985614,0.0261080118503237,1.93945689693884e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23477.Acetone,28914,-0.0516215580196134,0.00363062251553932,-0.0587375781500705,-0.0445055378891564,1.00539444521175e-45
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23478.Creatinine,28181,0.0544742241082704,0.00430276822690235,0.0460407983835418,0.062907649832999,1.2353793238508e-36
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23479.Albumin,28913,-0.0773315412654127,0.00365969300200037,-0.0845045395493335,-0.070158542981492,2.31184625598705e-98
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23480.Glycoprotein Acetyls,28916,0.152188507938302,0.00377608105121072,0.144787389077929,0.159589626798675,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23481.Concentration of Chylomicrons and Extremely Large VLDL Particles,28916,0.149720693991524,0.0037929766528634,0.142286459751912,0.157154928231136,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23482.Total Lipids in Chylomicrons and Extremely Large VLDL,28916,0.146261290006221,0.00378977978097851,0.138833321635503,0.153689258376939,1.66880539410363e-308
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23483.Phospholipids in Chylomicrons and Extremely Large VLDL,28916,0.152691747392714,0.00380538557698179,0.14523319166183,0.160150303123599,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23484.Cholesterol in Chylomicrons and Extremely Large VLDL,28916,0.145935518679274,0.00377885049632504,0.138528971706477,0.153342065652072,1.66880539396816e-308
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23485.Cholesteryl Esters in Chylomicrons and Extremely Large VLDL,28916,0.144351666945219,0.00376772938369849,0.13696691735317,0.151736416537268,1.66881193387458e-308
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23486.Free Cholesterol in Chylomicrons and Extremely Large VLDL,28916,0.142352023969661,0.00378335891079413,0.134936640504505,0.149767407434818,1.63071968215074e-302
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23487.Triglycerides in Chylomicrons and Extremely Large VLDL,28916,0.14100697349695,0.00377704550748027,0.133603964302288,0.148409982691611,5.84976479309019e-298
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23488.Concentration of Very Large VLDL Particles,28916,0.154186432201364,0.00380968377271869,0.146719452006835,0.161653412395893,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23489.Total Lipids in Very Large VLDL,28916,0.153790856826309,0.0038034881238769,0.14633602010351,0.161245693549108,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23490.Phospholipids in Very Large VLDL,28916,0.15422761444321,0.00377840450506965,0.146821941613274,0.161633287273147,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23491.Cholesterol in Very Large VLDL,28916,0.13887079004932,0.00371654195343683,0.131586367820584,0.146155212278056,1.80488087927304e-298
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23492.Cholesteryl Esters in Very Large VLDL,28916,0.125845233130509,0.0036800074550143,0.118632418518681,0.133058047742337,2.75125153527707e-251
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23493.Free Cholesterol in Very Large VLDL,28916,0.148733967295049,0.00375299448206871,0.141378098110195,0.156089836479904,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23494.Triglycerides in Very Large VLDL,28916,0.154765023829161,0.00384008087842252,0.147238465307453,0.162291582350869,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23495.Concentration of Large VLDL Particles,28916,0.14345703709496,0.00377457545892908,0.136058869195459,0.150855204994461,2.12040595053878e-308
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23496.Total Lipids in Large VLDL,28916,0.140384285797918,0.00377080762459299,0.132993502853716,0.14777506874212,2.31868107933956e-296
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23497.Phospholipids in Large VLDL,28916,0.149379138780108,0.00378025066631341,0.141969847474134,0.156788430086083,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23498.Cholesterol in Large VLDL,28916,0.13302245264525,0.00370589474504471,0.125758898944962,0.140286006345537,4.28590074680413e-276
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23499.Cholesteryl Esters in Large VLDL,28916,0.119109141771599,0.00365278083205772,0.111949691340766,0.126268592202432,4.52747557739629e-229
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23500.Free Cholesterol in Large VLDL,28916,0.145012377198098,0.00376802748555134,0.137627043326418,0.152397711069779,1.66880540589231e-308
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23501.Triglycerides in Large VLDL,28916,0.134561652321351,0.00379482282306535,0.127123799588143,0.141999505054559,1.26207278017444e-269
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23502.Concentration of Medium VLDL Particles,28916,0.074734248131288,0.00361241645060646,0.0676539118880993,0.0818145843744767,2.14201181699793e-94
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23503.Total Lipids in Medium VLDL,28916,0.0867985502859855,0.00363401684807196,0.0796758772637644,0.0939212233082066,7.12668753150748e-125
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23504.Phospholipids in Medium VLDL,28916,0.0703342648299815,0.00360671602971967,0.063265101411731,0.0774034282482321,3.75098087903082e-84
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23505.Cholesterol in Medium VLDL,28916,0.0257599406959011,0.00361664829324563,0.0186713100411397,0.0328485713506625,1.08385108715513e-12
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23506.Cholesteryl Esters in Medium VLDL,28916,0.00075069079034556,0.00365507257988415,-0.00641325146622737,0.00791463304691849,0.83727412991125
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23507.Free Cholesterol in Medium VLDL,28916,0.0567285039849231,0.00360073466390742,0.0496710640436645,0.0637859439261816,1.08771316778368e-55
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23508.Triglycerides in Medium VLDL,28916,0.11801417917284,0.00374358918331021,0.110676744373552,0.125351613972128,1.73732124707208e-214
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23509.Concentration of Small VLDL Particles,28916,0.109053499016676,0.00366285358822192,0.101874305983761,0.116232692049591,6.96660327934276e-192
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23510.Total Lipids in Small VLDL,28916,0.102512480475942,0.00365502032957252,0.0953486406299795,0.109676320321904,8.44707608029596e-171
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23511.Phospholipids in Small VLDL,28916,0.0762039091754868,0.00361384912544479,0.069120764889615,0.0832870534613586,5.77821198716103e-98
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23512.Cholesterol in Small VLDL,28916,0.0745470569782344,0.00360416912114233,0.0674828855007954,0.0816112284556733,2.35295758530987e-94
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23513.Cholesteryl Esters in Small VLDL,28916,0.0871418044749724,0.00361043962622013,0.0800653428075809,0.0942182661423639,1.91338171009325e-127
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23514.Free Cholesterol in Small VLDL,28916,0.0515891755279951,0.00360160924446517,0.0445300214088434,0.0586483296471468,2.23654050651748e-46
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23515.Triglycerides in Small VLDL,28916,0.12214421402428,0.00374966064668195,0.114794879156783,0.129493548891776,1.28125577145412e-228
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23516.Concentration of Very Small VLDL Particles,28916,0.0515116473328096,0.00365135742151731,0.0443549867866357,0.0586683078789836,4.81673144791495e-45
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23517.Total Lipids in Very Small VLDL,28916,0.0522735554336691,0.00366277887959845,0.0450945088296562,0.0594526020376821,4.72092779639102e-46
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23518.Phospholipids in Very Small VLDL,28916,0.067531648113648,0.00364869417933815,0.0603802075221453,0.0746830887051508,4.86133364687264e-76
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23519.Cholesterol in Very Small VLDL,28916,0.0137067051747368,0.00372133441775598,0.00641288971593506,0.0210005206335385,0.000230674424500821
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23520.Cholesteryl Esters in Very Small VLDL,28916,-0.000451063277364817,0.00375115737691929,-0.00780333173612662,0.00690120518139699,0.90428877576054
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23521.Free Cholesterol in Very Small VLDL,28916,0.0461507436645862,0.00366560009138748,0.0389661674854668,0.0533353198437057,2.97572430787099e-36
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23522.Triglycerides in Very Small VLDL,28916,0.104820975153073,0.00370554292087138,0.0975581110281653,0.112083839277981,1.14478158224917e-173
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23523.Concentration of IDL Particles,28916,0.00458459353677053,0.00365375917420712,-0.00257677444467542,0.0117459615182165,0.20957577772393
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23524.Total Lipids in IDL,28916,-0.0355773409956339,0.00374024185137336,-0.0429082150243257,-0.0282464669669422,2.00955617382759e-21
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23525.Phospholipids in IDL,28916,-0.0247190268590951,0.00374739499313484,-0.0320639210456394,-0.0173741326725508,4.28752251579471e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23526.Cholesterol in IDL,28916,-0.0502587656455434,0.0037500586694083,-0.0576088806375836,-0.0429086506535031,7.78175280661141e-41
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23527.Cholesteryl Esters in IDL,28916,-0.0516432687387295,0.00374786468869259,-0.058989083528567,-0.044297453948892,4.64142837058284e-43
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23528.Free Cholesterol in IDL,28916,-0.0452008585271372,0.00375009472747481,-0.0525510441929878,-0.0378506728612866,2.24198326312864e-33
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23529.Triglycerides in IDL,28916,0.0793760000711835,0.00369239549695625,0.0721389048971493,0.0866130952452178,1.03784074107104e-101
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23530.Concentration of Large LDL Particles,28916,0.0247481938894782,0.00361009725188139,0.0176724032757907,0.0318239845031658,7.26073361676703e-12
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23531.Total Lipids in Large LDL,28916,-0.0228574872187762,0.00364132994889719,-0.0299944939186147,-0.0157204805189377,3.49536064304112e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23532.Phospholipids in Large LDL,28916,-0.0204271912987913,0.00363701233343422,-0.0275557354723223,-0.0132986471252602,1.96681067879856e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23533.Cholesterol in Large LDL,28916,-0.0307015692991803,0.00364846404004099,-0.0378525588176606,-0.0235505797806999,4.11026343975249e-17
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23534.Cholesteryl Esters in Large LDL,28916,-0.0233781998221228,0.00363815712277698,-0.0305089877827657,-0.01624741186148,1.3318770405424e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23535.Free Cholesterol in Large LDL,28916,-0.0501437043784319,0.00368248869024536,-0.0573613822113128,-0.042926026545551,4.29248850134517e-42
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23536.Triglycerides in Large LDL,28916,0.0701124380227271,0.00369828947826907,0.0628637906453197,0.0773610854001345,1.15434611123846e-79
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23537.Concentration of Medium LDL Particles,28916,0.0402960148307783,0.00360308007952259,0.033233977874914,0.0473580517866426,5.6159526988749e-29
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23538.Total Lipids in Medium LDL,28916,0.023248156763011,0.00360674107353356,0.0161789442588853,0.0303173692671368,1.16840817179494e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23539.Phospholipids in Medium LDL,28916,0.0202586813300262,0.00360454236828056,0.0131937782881963,0.0273235843718561,1.92358862240241e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23540.Cholesterol in Medium LDL,28916,0.0182992926250001,0.00360505300734391,0.0112333887306061,0.0253651965193942,3.87827437013701e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23541.Cholesteryl Esters in Medium LDL,28916,0.0319768392248163,0.00361157113436201,0.0248981598014668,0.0390555186481658,8.91613598486965e-19
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23542.Free Cholesterol in Medium LDL,28916,-0.0193279357805771,0.00361175810878887,-0.0264069816738033,-0.0122488898873509,8.79437917703378e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23543.Triglycerides in Medium LDL,28916,0.0872896249662939,0.0037218826167957,0.0799947350373744,0.0945845148952135,1.64504487727245e-120
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23544.Concentration of Small LDL Particles,28916,0.0509817109291963,0.00359664943478586,0.043932278037016,0.0580311438213766,1.8645598794756e-45
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23545.Total Lipids in Small LDL,28916,0.0317926655819464,0.00360130471379206,0.024734108342914,0.0388512228209789,1.1235536900856e-18
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23546.Phospholipids in Small LDL,28916,0.0257079786743329,0.00360109355996196,0.0186498352968075,0.0327661220518583,9.62742755075365e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23547.Cholesterol in Small LDL,28916,0.0232633543104515,0.00360107156369764,0.0162052540456041,0.0303214545752988,1.06282402930288e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23548.Cholesteryl Esters in Small LDL,28916,0.0363620733211932,0.00360424050192184,0.0292977619374264,0.04342638470496,6.79056410107412e-24
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23549.Free Cholesterol in Small LDL,28916,-0.0127132710335866,0.00361370746606156,-0.0197961376670673,-0.00563040440010595,0.000435367015105219
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23550.Triglycerides in Small LDL,28916,0.114287278415439,0.00373796996030526,0.106960857293241,0.121613699537637,4.41487555132241e-202
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23551.Concentration of Very Large HDL Particles,28916,-0.126126995312049,0.00417386567847062,-0.134307772041852,-0.117946218582247,1.61892102161058e-197
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23552.Total Lipids in Very Large HDL,28916,-0.127790669145977,0.00419216842575755,-0.136007319260462,-0.119574019031492,6.62897846689154e-201
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23553.Phospholipids in Very Large HDL,28916,-0.123462624371384,0.00418582156389765,-0.131666834636624,-0.115258414106145,2.04966819681111e-188
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23554.Cholesterol in Very Large HDL,28916,-0.140889329459423,0.00418574293118939,-0.149093385604554,-0.132685273314292,1.16175620539099e-243
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23555.Cholesteryl Esters in Very Large HDL,28916,-0.157719494502012,0.00421329672119271,-0.16597755607555,-0.149461432928474,1.58397777416003e-299
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23556.Free Cholesterol in Very Large HDL,28916,-0.0788973969635011,0.00402377778356425,-0.086784001419287,-0.0710107925077152,4.74281036406583e-85
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23557.Triglycerides in Very Large HDL,28916,0.0425655247528409,0.00365603718278473,0.0353996918745828,0.049731357631099,2.94156256538726e-31
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23558.Concentration of Large HDL Particles,28916,-0.211774945167984,0.0042072399664177,-0.220021135502162,-0.203528754833805,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23559.Total Lipids in Large HDL,28916,-0.207088710251743,0.00418361679723705,-0.215288599174328,-0.198888821329159,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23560.Phospholipids in Large HDL,28916,-0.20043751777216,0.0041429116350722,-0.208557624576901,-0.192317410967418,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23561.Cholesterol in Large HDL,28916,-0.215985412939611,0.00419911272235527,-0.224215673875427,-0.207755152003794,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23562.Cholesteryl Esters in Large HDL,28916,-0.221608741885459,0.00418903362757825,-0.229819247795512,-0.213398235975406,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23563.Free Cholesterol in Large HDL,28916,-0.192476946432142,0.00421219371724939,-0.200732846117951,-0.184221046746333,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23564.Triglycerides in Large HDL,28916,-0.0150376174721274,0.00374389276348582,-0.0223756472885596,-0.0076995876556952,5.91998711845897e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23565.Concentration of Medium HDL Particles,28916,-0.184070874862959,0.00382284503079591,-0.191563651123319,-0.176578098602599,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23566.Total Lipids in Medium HDL,28916,-0.168236518425292,0.00379630927755345,-0.175677284609297,-0.160795752241288,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23567.Phospholipids in Medium HDL,28916,-0.148221531292911,0.00377883179713819,-0.155628041615302,-0.14081502097052,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23568.Cholesterol in Medium HDL,28916,-0.202838262013321,0.00382045758836775,-0.210326358886522,-0.19535016514012,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23569.Cholesteryl Esters in Medium HDL,28916,-0.204803805441228,0.00380304679338503,-0.212257777156263,-0.197349833726193,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23570.Free Cholesterol in Medium HDL,28916,-0.187681566197863,0.00388212590187435,-0.195290532965536,-0.180072599430189,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23571.Triglycerides in Medium HDL,28916,0.0611782296235084,0.00369577433672786,0.0539345119235218,0.068421947323495,2.89100901570538e-61
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23572.Concentration of Small HDL Particles,28916,-0.0727322089094133,0.00359048515683628,-0.0797695598168124,-0.0656948580020142,1.31549693109559e-90
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23573.Total Lipids in Small HDL,28916,-0.059045225875415,0.00362344611330094,-0.0661471802574848,-0.0519432714933452,1.96226803987334e-59
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23574.Phospholipids in Small HDL,28916,-0.0623444769116567,0.00363819550893307,-0.0694753401091655,-0.0552136137141479,1.68309564192827e-65
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23575.Cholesterol in Small HDL,28916,-0.0890951730469432,0.00357842792503021,-0.0961088917800024,-0.082081454313884,2.10239291667297e-135
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23576.Cholesteryl Esters in Small HDL,28916,-0.0882851120407152,0.0035681099908086,-0.0952786076227,-0.0812916164587303,9.15402286709045e-134
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23577.Free Cholesterol in Small HDL,28916,-0.0804578838249964,0.0036462799999598,-0.0876045926249176,-0.0733111750250752,5.16768582898924e-107
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23578.Triglycerides in Small HDL,28916,0.130225362774401,0.00381931465923529,0.1227395060423,0.137711219506502,7.46528282842169e-250
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23579.Phospholipids to Total Lipids in Chylomicrons and Extremely Large VLDL percentage,27682,0.0319894903649504,0.00369642348565789,0.0247445003330609,0.0392344803968399,5.22963201775211e-18
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23580.Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage,27682,-0.0521521432290094,0.00373604064131463,-0.059474782885986,-0.0448295035720327,3.90431143893867e-44
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23581.Cholesteryl Esters to Total Lipids in Chylomicrons and Extremely Large VLDL percentage,27682,-0.0311642353021481,0.00371163354666094,-0.0384390370536036,-0.0238894335506927,4.82231704125359e-17
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23582.Free Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage,27682,-0.0757448504529559,0.00376222261242251,-0.083118806773304,-0.0683708941326077,1.66193348933902e-89
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23583.Triglycerides to Total Lipids in Chylomicrons and Extremely Large VLDL percentage,27682,0.0290226908414924,0.0036924394970245,0.0217855094273244,0.0362598722556604,3.97932209636317e-15
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23584.Phospholipids to Total Lipids in Very Large VLDL percentage,28612,0.0760902808941451,0.00358810309419066,0.0690575988295314,0.0831229629587588,4.84566026386163e-99
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23585.Cholesterol to Total Lipids in Very Large VLDL percentage,28612,-0.102632086555776,0.00389763444789466,-0.110271450073649,-0.094992723037902,5.2387385258277e-151
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23586.Cholesteryl Esters to Total Lipids in Very Large VLDL percentage,28612,-0.109225273848651,0.00388506385995459,-0.116839999014162,-0.10161054868314,1.42248626542265e-171
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23587.Free Cholesterol to Total Lipids in Very Large VLDL percentage,28612,-0.050875114311998,0.00381995299379261,-0.0583622221798315,-0.0433880064441644,2.39151307700841e-40
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23588.Triglycerides to Total Lipids in Very Large VLDL percentage,28612,0.0662540325015186,0.0038258526282266,0.0587553613501945,0.0737527036528427,7.6234082819491e-67
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23589.Phospholipids to Total Lipids in Large VLDL percentage,28911,0.140604831590497,0.00374745175758869,0.133259826145624,0.147949837035371,7.23472491226704e-301
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23590.Cholesterol to Total Lipids in Large VLDL percentage,28911,-0.0260814870298929,0.00371555314036124,-0.0333639711850009,-0.0187990028747849,2.27505901848924e-12
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23591.Cholesteryl Esters to Total Lipids in Large VLDL percentage,28911,-0.0614511277346373,0.00383722579565117,-0.0689720902941136,-0.053930165175161,1.790899270927e-57
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23592.Free Cholesterol to Total Lipids in Large VLDL percentage,28911,0.0583009319748982,0.00362788226798534,0.051190282729647,0.0654115812201495,7.35285785991834e-58
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23593.Triglycerides to Total Lipids in Large VLDL percentage,28911,-0.0421231965442318,0.00359978967925265,-0.049178784315567,-0.0350676087728966,1.47419228603607e-31
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23594.Phospholipids to Total Lipids in Medium VLDL percentage,28916,-0.0549196063295614,0.00378930755156402,-0.0623466491306269,-0.047492563528496,1.9596126544499e-47
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23595.Cholesterol to Total Lipids in Medium VLDL percentage,28916,-0.105970152088545,0.00391725699709601,-0.113647975802853,-0.0982923283742369,3.47458708843479e-159
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23596.Cholesteryl Esters to Total Lipids in Medium VLDL percentage,28916,-0.114433301958672,0.00393684411329329,-0.122149516420727,-0.106717087496618,4.03489876231788e-183
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23597.Free Cholesterol to Total Lipids in Medium VLDL percentage,28916,-0.0789557421044866,0.00384710626766258,-0.0864960703891053,-0.071415413819868,6.12654716478449e-93
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23598.Triglycerides to Total Lipids in Medium VLDL percentage,28916,0.0957655728683335,0.00389476649046968,0.0881318305470129,0.103399315189654,3.85222669772281e-132
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23599.Phospholipids to Total Lipids in Small VLDL percentage,28916,-0.0982055032597515,0.00381511640663192,-0.10568313141675,-0.0907278751027529,1.72517013131476e-144
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23600.Cholesterol to Total Lipids in Small VLDL percentage,28916,-0.0490810260945516,0.00373813216219569,-0.0564077651324551,-0.041754287056648,2.8784953830117e-39
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23601.Cholesteryl Esters to Total Lipids in Small VLDL percentage,28916,-0.00527071883495556,0.0036636639866229,-0.0124515002487364,0.00191006257882532,0.150261419779068
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23602.Free Cholesterol to Total Lipids in Small VLDL percentage,28916,-0.105355803959582,0.00383180886300306,-0.112866149331068,-0.0978454585880957,2.62626889013235e-164
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23603.Triglycerides to Total Lipids in Small VLDL percentage,28916,0.0647774766948631,0.00376522081070463,0.057397643905882,0.0721573094838441,5.27210220977379e-66
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23604.Phospholipids to Total Lipids in Very Small VLDL percentage,28916,0.141734712426807,0.00368278708493269,0.134516449740338,0.148952975113275,1.66880540556138e-308
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23605.Cholesterol to Total Lipids in Very Small VLDL percentage,28916,-0.11561410663007,0.00388520285405664,-0.123229104224021,-0.107999109036119,1.08357629753201e-191
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23606.Cholesteryl Esters to Total Lipids in Very Small VLDL percentage,28916,-0.126434000049293,0.00391391467885743,-0.134105272819854,-0.118762727278733,6.23966598329902e-225
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23607.Free Cholesterol to Total Lipids in Very Small VLDL percentage,28916,-0.0172116583662985,0.00365285080245188,-0.0243712459391041,-0.0100520707934928,2.4662831193872e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23608.Triglycerides to Total Lipids in Very Small VLDL percentage,28916,0.0937866926315299,0.00387882780615722,0.0861841901314618,0.101389195131598,6.88873042024769e-128
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23609.Phospholipids to Total Lipids in IDL percentage,28916,0.0756402730584515,0.00357364297507992,0.0686359328272949,0.0826446132896082,1.1007387625872e-98
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23610.Cholesterol to Total Lipids in IDL percentage,28916,-0.117829678930707,0.00372580319230896,-0.125132253187632,-0.110527104673781,7.94585611808152e-216
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23611.Cholesteryl Esters to Total Lipids in IDL percentage,28916,-0.111467047156511,0.00370155736706445,-0.118722099595958,-0.104211994717065,3.47271212695676e-196
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23612.Free Cholesterol to Total Lipids in IDL percentage,28916,-0.0539452848468161,0.00367029869786479,-0.0611390702946311,-0.0467514993990011,9.98862076863292e-49
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23613.Triglycerides to Total Lipids in IDL percentage,28916,0.116450315092772,0.00380626222498476,0.108990041131802,0.123910589053742,2.46066472917827e-202
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23614.Phospholipids to Total Lipids in Large LDL percentage,28916,0.0236601422691689,0.00362112870928746,0.0165627299989655,0.0307575545393724,6.51376127764545e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23615.Cholesterol to Total Lipids in Large LDL percentage,28916,-0.119628057623223,0.00378793588544933,-0.127052411958703,-0.112203703287742,3.04908823101397e-215
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23616.Cholesteryl Esters to Total Lipids in Large LDL percentage,28916,-0.0224124968570886,0.00360756571562819,-0.0294833256597198,-0.0153416680544573,5.28126450418538e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23617.Free Cholesterol to Total Lipids in Large LDL percentage,28916,-0.143765701863136,0.00388701744224347,-0.151384256049933,-0.136147147676339,1.28148295005112e-292
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23618.Triglycerides to Total Lipids in Large LDL percentage,28916,0.101303084857381,0.00376050690111974,0.0939324913311866,0.108673678383576,6.91973586278513e-158
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23619.Phospholipids to Total Lipids in Medium LDL percentage,28916,-0.0308496487756242,0.00363108073018579,-0.0379665670067884,-0.0237327305444601,2.05527881012089e-17
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23620.Cholesterol to Total Lipids in Medium LDL percentage,28916,-0.0540163405670057,0.00365771120766202,-0.0611854545340232,-0.0468472265999881,3.57179339015067e-49
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23621.Cholesteryl Esters to Total Lipids in Medium LDL percentage,28916,0.0812510350009493,0.00367533064585034,0.0740473869350826,0.0884546830668159,2.0992389157465e-107
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23622.Free Cholesterol to Total Lipids in Medium LDL percentage,28916,-0.148906355001287,0.00384714108524825,-0.156446751528373,-0.1413659584742,1.66880539388402e-308
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23623.Triglycerides to Total Lipids in Medium LDL percentage,28916,0.0748677625685913,0.0037038625637312,0.0676081919436781,0.0821273331935044,3.1402218379992e-90
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23624.Phospholipids to Total Lipids in Small LDL percentage,28916,-0.0349797468098472,0.00364451195862377,-0.0421229902487498,-0.0278365033709446,8.79095165646643e-22
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23625.Cholesterol to Total Lipids in Small LDL percentage,28916,-0.0538697956377088,0.00362217200148562,-0.0609692527606206,-0.046770338514797,7.63412432768605e-50
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23626.Cholesteryl Esters to Total Lipids in Small LDL percentage,28916,0.0429681238700956,0.00363841712007571,0.0358368263147472,0.050099421425444,4.12954980861686e-32
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23627.Free Cholesterol to Total Lipids in Small LDL percentage,28916,-0.110965879898022,0.00375096876341572,-0.118317778674316,-0.103613981121727,1.64728415421774e-189
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23628.Triglycerides to Total Lipids in Small LDL percentage,28916,0.107658993189319,0.00376858550084795,0.100272565607657,0.115045420770981,4.93594182340985e-177
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23629.Phospholipids to Total Lipids in Very Large HDL percentage,28902,-0.093316325956121,0.00404749145439357,-0.101249409206732,-0.0853832427055096,1.46881355769082e-116
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23630.Cholesterol to Total Lipids in Very Large HDL percentage,28902,0.0113279380822421,0.00380455238531996,0.00387101540701496,0.0187848607574692,0.00290879777404013
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23631.Cholesteryl Esters to Total Lipids in Very Large HDL percentage,28902,-0.102741299026442,0.00360304643064122,-0.109803270030499,-0.0956793280223855,2.12104033873107e-176
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23632.Free Cholesterol to Total Lipids in Very Large HDL percentage,28902,0.173284648326652,0.00417725782469243,0.165097222990255,0.181472073663049,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23633.Triglycerides to Total Lipids in Very Large HDL percentage,28902,0.136057660486759,0.00394299942165386,0.128329381620317,0.1437859393532,1.01709477392612e-255
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23634.Phospholipids to Total Lipids in Large HDL percentage,28916,0.099758591981765,0.00395662018112999,0.0920036164267502,0.10751356753678,9.12331709420943e-139
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23635.Cholesterol to Total Lipids in Large HDL percentage,28916,-0.153616018849378,0.00400330877527391,-0.161462504048915,-0.145769533649842,1.66880613549954e-308
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23636.Cholesteryl Esters to Total Lipids in Large HDL percentage,28916,-0.15578377132666,0.00393275181329987,-0.163491964880728,-0.148075577772592,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23637.Free Cholesterol to Total Lipids in Large HDL percentage,28916,-0.0465849144754465,0.00396050770513582,-0.0543475095775127,-0.0388223193733803,7.21241563882787e-32
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23638.Triglycerides to Total Lipids in Large HDL percentage,28916,0.152567077981079,0.00384854751467774,0.14502392485231,0.160110231109847,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23639.Phospholipids to Total Lipids in Medium HDL percentage,28916,0.211715155015766,0.00385061137519194,0.20416795672039,0.219262353311143,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23640.Cholesterol to Total Lipids in Medium HDL percentage,28916,-0.195661699415041,0.00381281708003712,-0.203134820891914,-0.188188577938168,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23641.Cholesteryl Esters to Total Lipids in Medium HDL percentage,28916,-0.167059048003476,0.00374477506422759,-0.174398807129362,-0.15971928887759,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23642.Free Cholesterol to Total Lipids in Medium HDL percentage,28916,-0.196397707593796,0.00406900183023439,-0.204372951181056,-0.188422464006537,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23643.Triglycerides to Total Lipids in Medium HDL percentage,28916,0.16797471114445,0.00376506908972696,0.160595175728585,0.175354246560315,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23644.Phospholipids to Total Lipids in Small HDL percentage,28916,-0.0286675660405557,0.00371774849615669,-0.0359543530930228,-0.0213807789880886,1.28836215981464e-14
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23645.Cholesterol to Total Lipids in Small HDL percentage,28916,-0.0931149752769873,0.00367320622784058,-0.100314459483555,-0.0859154910704197,3.08631491945567e-140
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23646.Cholesteryl Esters to Total Lipids in Small HDL percentage,28916,-0.0748531967377569,0.00366315442958676,-0.082032979419747,-0.0676734140557669,3.73410444998638e-92
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23647.Free Cholesterol to Total Lipids in Small HDL percentage,28916,-0.065252802012694,0.00385445872187001,-0.0728075411075592,-0.0576980629178287,5.58140658985672e-64
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23648.Triglycerides to Total Lipids in Small HDL percentage,28916,0.186535778187285,0.00380760673995116,0.179072868976981,0.193998687397589,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24003.Nitrogen dioxide air pollution; 2010,49823,-0.000729673095146187,0.00319374134551307,-0.00698940613235181,0.00553005994205943,0.819282054820295
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24004.Nitrogen oxides air pollution; 2010,49823,-0.00123225533340774,0.00311636971215446,-0.00734033996923049,0.004875829302415,0.692539280399503
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24005.Particulate matter air pollution (pm10); 2010,46462,-0.00155267053707691,0.0029985628306889,-0.00742985368522716,0.00432451261107333,0.604596862926743
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24006.Particulate matter air pollution (pm2.5); 2010,46462,0.00330688521502878,0.00326353300614898,-0.00308963947702322,0.00970340990708078,0.310929888345835
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24007.Particulate matter air pollution (pm2.5) absorbance; 2010,46462,-0.00662859069793089,0.00322004125400442,-0.0129398715557796,-0.000317309840082224,0.0395436824596969
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24008.Particulate matter air pollution 2.5-10um; 2010,46462,-0.00620242399743715,0.00295288550560524,-0.0119900795884234,-0.000414768406450873,0.0356935910515572
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24009.Traffic intensity on the nearest road,49823,-0.100499628159597,0.0303222733559508,-0.159931283937261,-0.0410679723819338,0.000919111121987154
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24010.Inverse distance to the nearest road,49823,-0.000178330188294754,0.00279137592854189,-0.00564942700823686,0.00529276663164736,0.949061157633168
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24011.Traffic intensity on the nearest major road,49823,0.00621922126294921,0.00279247709171448,0.00074596616318883,0.0116924763627096,0.0259427569202883
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24012.Inverse distance to the nearest major road,49823,-0.00639151250075363,0.00283069669999712,-0.011939678032748,-0.000843346968759266,0.0239543884925256
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24013.Total traffic load on major roads,49823,-0.0367432347410253,0.020774084539052,-0.0774604404375673,0.00397397095551663,0.0769491761316694
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24015.Sum of road length of major roads within 100m,49823,-0.049017963259613,0.0202152963887749,-0.0886399441816119,-0.00939598233761414,0.0153205373498674
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24016.Nitrogen dioxide air pollution; 2005,49823,-0.00514199129091922,0.00318905348223079,-0.0113925361160916,0.00110855353425312,0.106883888761265
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24017.Nitrogen dioxide air pollution; 2006,49823,-0.00538676361257021,0.00318517203314639,-0.0116297007975371,0.000856173572396709,0.0908048268490873
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24018.Nitrogen dioxide air pollution; 2007,49823,-0.00649535981231035,0.00315179645468429,-0.0126728808634916,-0.000317838761129134,0.0393231351782038
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24019.Particulate matter air pollution (pm10); 2007,49722,0.00274329811435737,0.00309139164983723,-0.0033158295193236,0.00880242574803835,0.374868370698776
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24020.Average daytime sound level of noise pollution,49823,-0.00515962559416931,0.00280201003137575,-0.0106515652556658,0.000332314067327158,0.065568679404392
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24021.Average evening sound level of noise pollution,49823,-0.00510486395665899,0.00280183725445902,-0.0105964649753987,0.000386737062080688,0.0684655028659763
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24022.Average night-time sound level of noise pollution,49823,-0.00516999182877856,0.00280201151158739,-0.0106619343914898,0.000321950733932721,0.0650289053691539
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24023.Average 16-hour sound level of noise pollution,49823,-0.00518316255564516,0.00280192649502018,-0.0106749384858847,0.000308613374594387,0.0643401223529549
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24024.Average 24-hour sound level of noise pollution,49823,-0.00515051798186591,0.00280189507713995,-0.0106422323330602,0.000341196369328393,0.0660349769908173
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2405.Number of children fathered,22938,0.0336174276064672,0.0227410453523591,-0.0109550212841566,0.0781898764970911,0.13934899863809
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,"X24500.Greenspace percentage, buffer 1000m",44458,-0.00145746413625168,0.00327194598121764,-0.00787047825943827,0.0049555499869349,0.656002099394512
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,"X24501.Domestic garden percentage, buffer 1000m",44458,0.00946563493933259,0.00296430383499113,0.00365559942274997,0.0152756704559152,0.00140800198285297
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,"X24502.Water percentage, buffer 1000m",44458,-0.0091147404040655,0.00295000744185758,-0.0148967549901063,-0.00333272581802464,0.00200458990661772
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,"X24503.Greenspace percentage, buffer 300m",44458,-2.3154987303883e-05,0.00308078009251622,-0.00606148396863567,0.0060151739940279,0.994003230202806
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,"X24504.Domestic garden percentage, buffer 300m",44458,0.00694827171117748,0.00299052928117968,0.0010868343200653,0.0128097091022897,0.0201607985182764
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,"X24505.Water percentage, buffer 300m",44458,-0.00618067649344589,0.0029637844709403,-0.0119896940564889,-0.0003716589304029,0.0370386867492683
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,"X24506.Natural environment percentage, buffer 1000m",50068,-0.00527308838995892,0.00313961534843002,-0.0114267344728818,0.000880557692963908,0.0930544040532604
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,"X24507.Natural environment percentage, buffer 300m",50068,-0.00107403206431536,0.0029526847353682,-0.00686129414563703,0.00471323001700631,0.716048011499467
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24508.Distance (Euclidean) to coast,50068,0.00585863248343041,0.00280491386928281,0.000361001299636112,0.0113562636672247,0.0367394907590112
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2684.Years since last breast cancer screening  or  mammogram,10984,0.0381057665941137,0.0301791126697704,-0.0210452942386363,0.0972568274268637,0.206740519355625
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2704.Years since last cervical smear test,20685,0.017213731784494,0.0218614904061525,-0.025634789411565,0.0600622529805529,0.431056929008901
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2714.Age when periods started (menarche),26390,0.012887559891251,0.0186099043558106,-0.0235878526461377,0.0493629724286398,0.488622697956265
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2734.Number of live births,27206,0.034008088935265,0.0179845186363406,-0.00124156759196248,0.0692577454624925,0.0586396863752758
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2744.Birth weight of first child,21589,-0.0764745900042169,0.0200160509528524,-0.115706049871808,-0.0372431301366262,0.000133466446827575
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2754.Age at first live birth,18396,-0.0295402107723786,0.00484158085971817,-0.0390297092574262,-0.020050712287331,1.07277497934354e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2764.Age at last live birth,18344,-0.0179252918264715,0.0046733720658958,-0.0270851010756273,-0.00876548257731575,0.000125665938624208
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2794.Age started oral contraceptive pill,20856,-0.00269429387821477,0.00525885966624662,-0.0130016588240581,0.00761307106762862,0.608422533352533
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2804.Age when last used oral contraceptive pill,18916,-0.00372123392822117,0.00453675936591677,-0.012613282285418,0.0051708144289757,0.412089341082442
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X2867.Age started smoking in former smokers,12327,-0.00793109480020698,0.00572551485706357,-0.0191531039200516,0.00329091431963763,0.166010455067125
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,"X28735.Feeling anxious, nervous or on edge over the last 2 weeks",19237,-0.00800891752856382,0.0266947986860039,-0.0603307229531314,0.0443128878960038,0.764166743914245
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X28736.Not being able to stop or control worrying over the last 2 weeks,19230,-0.0293551220521399,0.0295840216886683,-0.0873398045619298,0.0286295604576499,0.321081875724307
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X28737.Little interest or pleasure in doing things over the last 2 weeks,19266,-0.00579049561080059,0.0304134352731977,-0.0654008287462681,0.0538198375246669,0.849003436785263
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,"X28738.Feeling down, depressed or hopeless over the last 2 weeks",19213,0.0118603783956123,0.0295943318568023,-0.0461445120437201,0.0698652688349447,0.688597460806795
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X28739.Difficulty with standing for long periods,19282,0.0888524230493757,0.0258227744207113,0.0382397851847815,0.13946506091397,0.000581108571954946
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X28740.Difficulty with taking care of household responsibilities,19329,0.0606305189476809,0.0286322388657648,0.00451133077078192,0.11674970712458,0.0342249885877135
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X28741.Difficulty learning a new task,19176,0.0549582096830907,0.0323914946670759,-0.00852911986437802,0.118445539230559,0.0897722019865119
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X28742.Difficulty with joining in community activities,18477,-0.0270319614088762,0.0328149090297162,-0.0913491831071199,0.0372852602893675,0.410080486953628
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X28743.Difficulty with being emotionally affected by health problems,19204,0.0388207152383215,0.0277792544297313,-0.0156266234439519,0.093268053920595,0.162288001399148
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X28744.Difficulty with concentrating on doing something for ten minutes,19328,0.0453366093172604,0.0391025870505695,-0.0313044613018559,0.121977679936377,0.246296364922806
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X2887.Number of cigarettes previously smoked daily,11708,0.0475558813971874,0.0293181114375706,-0.00990761702045091,0.105019379814826,0.104816398858909
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X2897.Age stopped smoking,12335,0.0497959888788682,0.00597101011317267,0.0380928090570497,0.0614991687006866,8.24115624594305e-17
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29001#0.Mental health conditions experienced by first degree blood relatives_None of the above,17248,-0.00990247762452819,0.00987194049535587,-0.0292514809954257,0.00944652574636932,0.315829918050234
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29001#1.Mental health conditions experienced by first degree blood relatives_Depression,17248,0.012754709822174,0.0107473188166094,-0.00831003505838035,0.0338194547027283,0.235330519095282
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29001#3.Mental health conditions experienced by first degree blood relatives_Schizophrenia,17248,0.0157222373872734,0.0358231785633309,-0.0544911925968551,0.0859356673714019,0.660750738913289
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29001#4.Mental health conditions experienced by first degree blood relatives_Any other type of psychosis or psychotic illness,17248,-0.0406466879345706,0.0367588494358984,-0.112694032828931,0.0314006569597902,0.268843226546243
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29001#5.Mental health conditions experienced by first degree blood relatives_A personality disorder,17248,0.0681700889920686,0.0407557458809077,-0.0117111729345104,0.148051350918648,0.0944144138309563
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29001#7.Mental health conditions experienced by first degree blood relatives_Attention deficit or attention deficit and hyperactivity disorder,17248,-0.000351650218279752,0.0346055302051311,-0.0681784894203367,0.0674751889837772,0.991892412010489
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29001#8.Mental health conditions experienced by first degree blood relatives_An anxiety disorder,17248,0.0221747334674751,0.0154865968621946,-0.00817899638242635,0.0525284633173765,0.152200273114986
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29001#9.Mental health conditions experienced by first degree blood relatives_An eating disorder,17248,-0.0198480147044387,0.028001522882802,-0.0747309995547306,0.0350349701458533,0.478446321123156
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29002.Recent lack of interest or pleasure in doing things,17129,0.0249178927796973,0.0308319585734541,-0.0355127460242728,0.0853485315836674,0.418995954002689
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29003.Recent feelings of depression,17113,0.00842194758440733,0.029963612879992,-0.050306733660377,0.0671506288291917,0.778658194283205
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,"X29004.Trouble falling or staying asleep, or sleeping too much",17137,0.0644022175734585,0.0242262029878998,0.016918859717175,0.111885575429742,0.00785925547840527
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29005.Recent feelings of tiredness or low energy,17145,0.0854442642241582,0.0243406091680053,0.0377366702548678,0.133151858193448,0.000448652716682337
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29006.Recent poor appetite or overeating,17160,0.0212230650855606,0.0336964556535542,-0.0448219879954056,0.0872681181665268,0.528813695910706
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29007.Recent feelings of inadequacy,17091,-0.0120285383999808,0.0325658972677628,-0.075857697044796,0.0518006202448344,0.71186402123698
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29008.Recent trouble concentrating on things,17155,0.0350355880087443,0.0319523978864466,-0.0275911118486911,0.0976622878661796,0.272878389981535
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29009.Recent changes in speed or amount of moving or speaking,17141,0.075245178873214,0.0553573294593626,-0.0332551868671366,0.183745544613565,0.174081110547506
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29010.Recent thoughts of suicide or self-harm,17057,0.0343983133617519,0.0616180654727204,-0.08637309496478,0.155169721688284,0.576680702934105
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29038#0.Substances taken for depression_None of options listed,15821,-0.0024914364900688,0.0193896443568151,-0.0404951394294264,0.0355122664492888,0.897760353103073
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29038#1.Substances taken for depression_Drugs or alcohol (more than once),15821,-0.08927781967251,0.0373417881485696,-0.162467724443706,-0.0160879149013137,0.0168220213467051
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29038#2.Substances taken for depression_Medication prescribed to participant (for at least 2 weeks),15821,-0.00353837907002043,0.0192049776779608,-0.0411801353188236,0.0341033771787827,0.853825339519362
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29038#3.Substances taken for depression_Unprescribed medication (more than once),15821,0.0291546277112393,0.0553397320353237,-0.0793112470779952,0.137620502500474,0.598319082180772
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29039#1.Use of specific medications_Citalopram (sometimes called Cipramil),15821,-0.0508272612337871,0.0358287367449407,-0.121051585253871,0.0193970627862966,0.156030372029446
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29039#2.Use of specific medications_Fluoxetine (Prozac or Oxactin),15821,0.0142948720113334,0.0382907364717666,-0.0607549714733292,0.089344715495996,0.708911912153182
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29039#3.Use of specific medications_Sertraline (Lustral),15821,-0.00864983315049568,0.0430748205114306,-0.0930764813528997,0.0757768150519083,0.840850118251937
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29039#5.Use of specific medications_Amitriptyline (Elavil),15821,0.0403422884514427,0.0506020598725596,-0.058837748898774,0.13952232580166,0.425320166011202
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29039#7.Use of specific medications_Other antidepressant(s),15821,-0.000394749544602363,0.0373283496459294,-0.073558314850624,0.0727688157614193,0.991562613457462
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29047#0.Activities undertaken to treat depression_None of options listed,15821,-0.00875238081418094,0.0189768314191971,-0.0459469703958072,0.0284422087674453,0.644651405869282
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29051#0.Manifestations of mania or irritability_None of options listed,15821,-0.00723183465546045,0.0292787231435677,-0.0646181320168531,0.0501544627059322,0.804911695074452
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29051#1.Manifestations of mania or irritability_More active than usual,15821,0.00421204764123554,0.0458245741749732,-0.085604117741712,0.0940282130241831,0.926765318297158
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29051#2.Manifestations of mania or irritability_More confident than usual,15821,0.00978400137460735,0.0586315107002005,-0.105133759597786,0.124701762347,0.867472310023106
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29051#3.Manifestations of mania or irritability_Easily distracted,15821,-0.0252582633142381,0.0368686814959336,-0.0975208790462679,0.0470043524177917,0.493298916196362
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29051#4.Manifestations of mania or irritability_More creative or had more ideas than usual,15821,0.0470957256553344,0.0596732860678946,-0.0698639150377389,0.164055366348408,0.429991601378829
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29051#5.Manifestations of mania or irritability_Neded less sleep than usual,15821,0.0248342413997254,0.0576374888960808,-0.088135236836593,0.137803719636044,0.666569068800422
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29051#6.Manifestations of mania or irritability_Thoughts were racing,15821,-0.0454945292000847,0.0317853669432725,-0.107793848408899,0.0168047900087294,0.152362820775697
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29051#7.Manifestations of mania or irritability_More restless than usual,15821,-0.00152652252049197,0.0309258149298843,-0.0621411197830652,0.0590880747420813,0.960632402242134
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29051#8.Manifestations of mania or irritability_More talkative than usual,15821,0.0525016908746568,0.0437838570105038,-0.0333146688659306,0.138318050615244,0.230502883770678
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29058.Recent feelings or nervousness or anxiety,16883,-0.000196701703427251,0.028380245036583,-0.0558219819751299,0.0554285785682754,0.99447003825212
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29059.Recent inability to stop or control worrying,16901,0.030523634946961,0.0293734560491459,-0.0270483389093651,0.088095608803287,0.298746565724119
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29060.Recent worrying too much about different things,16892,-0.00260508776469787,0.0270985123781254,-0.0557181720258236,0.0505079964964279,0.923415308042597
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29061.Recent trouble relaxing,16893,0.0217949984532363,0.0286233518692154,-0.0343067712104259,0.0778967681168986,0.44640424598411
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29062.Recent restlessness,16912,0.0290478062179027,0.0404814292558726,-0.0502957951236076,0.108391407559413,0.473039282639192
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29063.Recent easy annoyance or irritability,16869,0.0020711498517875,0.0290437803498922,-0.0548546596340013,0.0589969593375763,0.943150844958948
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29064.Recent feelings of foreboding,16860,0.0610724020626985,0.0328640957809809,-0.00334122566802404,0.125486029793421,0.0631393094406306
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29065#1.Symptoms of panic attack_Heart was pounding or racing,15821,-0.0231764563130086,0.0201568929375207,-0.0626839664705493,0.016331053844532,0.250242407927587
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29065#11.Symptoms of panic attack_Felt like things weren't real or detached from self,15821,0.00755579446198349,0.0338019187076378,-0.0586959662049866,0.0738075551289536,0.823124738396564
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29065#12.Symptoms of panic attack_Afraid of losing control or 'going crazy',15821,-0.0633289643743811,0.043404165672122,-0.14840112909174,0.0217432003429781,0.144570478533398
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29065#13.Symptoms of panic attack_Afraid I was going to die,15821,0.0637092098550834,0.0464208362893061,-0.0272756292719565,0.154694048982123,0.169950017500152
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29065#2.Symptoms of panic attack_Sweating,15821,0.0285714790351391,0.030605099122291,-0.0314145152445513,0.0885574733148295,0.350548830495136
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29065#3.Symptoms of panic attack_Trembling or shaking,15821,0.0305057462138501,0.0326988436537339,-0.0335839873474683,0.0945954797751686,0.350870140116637
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29065#6.Symptoms of panic attack_Pain or discomfort in chest,15821,-0.00194776715340779,0.0329165563975476,-0.066464217692601,0.0625686833857855,0.952815165392861
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29065#7.Symptoms of panic attack_Nauseous or felt sick in the stomach,15821,0.0317482479966135,0.030404199691742,-0.0278439833992007,0.0913404793924278,0.296406056160964
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29065#9.Symptoms of panic attack_Felt hot or cold,15821,0.0171896493130773,0.0406479691265208,-0.0624803701749035,0.096859668801058,0.672380739696069
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29076.Felt loved as a child,16830,-0.00471910966766932,0.0250061281188521,-0.0537311207806194,0.0442929014452808,0.850316021176353
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29077.Physically abused by family as a child,16855,-0.00550226309331769,0.0337260714789112,-0.0716053631919837,0.0606008370053483,0.870405686707068
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29078.Felt hated by family member as a child,16829,0.0506405547451604,0.0338665329044298,-0.015737849747522,0.117018959237843,0.134855488685799
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29079.Sexually molested as a child,16704,0.116695113876762,0.0450380724939161,0.0284204917886867,0.204969735964838,0.00957716988077443
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29080.Someone to take to doctor when needed as a child,16795,-0.0748108392119851,0.036213935913942,-0.145790153603311,-0.00383152482065865,0.0388624491277785
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29081.Stopped from seeing friends or family by partner or ex-partner as an adult,16836,0.02972369765463,0.0469717918610511,-0.0623410143930301,0.12178840970229,0.526873585059072
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29082.Belittlement by partner or ex-partner as an adult,16733,0.0340931265964931,0.0367885987071196,-0.0380125268694613,0.106198780062447,0.354079712674829
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29083.Physical violence by partner or ex-partner as an adult,16846,-0.00271698107893959,0.041726009539331,-0.0844999597760284,0.0790659976181492,0.948083364099891
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29084.Sexual interference by partner or ex-partner without consent as an adult,16800,0.0157357832121187,0.057946106504791,-0.0978385855372716,0.129310151961509,0.785964514768858
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29085.Sexual intercourse by partner or ex-partner without consent as an adult,16798,-0.00192732639396088,0.0557699346729362,-0.111236398352916,0.107381745564994,0.972432189078598
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29086.Experienced a violent or sexual assault,16847,-0.00169895106305247,0.0469617283021056,-0.0937439385351794,0.0903460364090745,0.971141372166202
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29087.Experienced a life-threatening injury or illness,16849,0.0599298078278221,0.0293750215865439,0.00235476551819613,0.117504850137448,0.0413497496807246
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29088.Experienced a marital separation or divorce,16855,-0.0107814829768549,0.0275815149002089,-0.0648412521812644,0.0432782862275546,0.695879615146298
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29089.Experienced the death of a spouse or partner,16875,0.0156258586024029,0.0374749156590088,-0.0578249760892544,0.0890766932940602,0.676706771972475
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29090.Experienced the death of a close friend or family member due to suicide,16852,-0.0500896910628135,0.0347820049303046,-0.11826242072621,0.0180830386005835,0.149856679382277
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29091.Frequency of drinking alcohol,16859,-0.308601296092038,0.0229027171421481,-0.353490621690649,-0.263711970493428,3.61420518407102e-41
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29092.Amount of alcohol drunk on a typical drinking day,15038,-0.270244782572365,0.0268687238238659,-0.322907481267142,-0.217582083877587,1.00721389428309e-23
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29093.Frequency of consuming six or more units of alcohol,15071,-0.26930085288637,0.027165425449338,-0.322545086767072,-0.216056619005667,4.28600278127914e-23
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29104.Ever used cannabis,16846,-0.0856636450204511,0.0329543974899873,-0.150254264100826,-0.021073025940076,0.00934520071071306
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29108.Ever thought that life not worth living,16767,0.0549554771163424,0.0284861244128343,-0.00087732673281285,0.110788280965498,0.0537227086528159
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29109.Ever contemplated self-harm,16812,0.0837875436599413,0.0379346755401874,0.00943557960117407,0.158139507718709,0.0272067158157568
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29111.Ever self-harmed,16836,0.148093891233829,0.0603032129480055,0.0298995938557381,0.26628818861192,0.0140663574990892
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X29132.Ever had recurrent episodes of excessive overeating or binge eating,16831,0.000557742856405811,0.0413608971939636,-0.0805096156437629,0.0816251013565746,0.989241183310114
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X29136#1.Actions and feelings during periods of overeating or binge eating_Eaten much more rapidly than normal,17074,0.0440951136318335,0.043423698080783,-0.0410153346065011,0.129205561870168,0.309900070837778
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X29136#2.Actions and feelings during periods of overeating or binge eating_Eaten until feeling uncomfortably full,17074,0.0384474669559331,0.033310021164106,-0.0268401745257146,0.103735108437581,0.248421547403107
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X29136#3.Actions and feelings during periods of overeating or binge eating_Eaten large amounts of food when not physically hungry,17074,0.0810416840018668,0.0358000643624199,0.0108735578515238,0.15120981015221,0.0236032231466694
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X29136#4.Actions and feelings during periods of overeating or binge eating_Eaten alone because of feeling embarrassed by overeating,17074,0.0723496172990811,0.0487095312370047,-0.023121063925448,0.16782029852361,0.13747550782372
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X29149.Dependency of self-esteem on body shape or weight currently,16815,-0.0888799995197378,0.025964923913643,-0.139771250390478,-0.0379887486489975,0.000620636299120441
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X29153.Pain or discomfort today,16841,0.049672583520266,0.0243060669547181,0.00203269228901853,0.0973124747515134,0.0410057529767144
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29154.Anxiety or depression today,16841,0.0375470326780431,0.0301886114759829,-0.0216226458148834,0.0967167111709696,0.21360956146003
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29166.Frequency of confiding in someone close,16433,-0.0500175205405056,0.0236437879427735,-0.0963593449083417,-0.00367569617266943,0.0344056629110256
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29167#0.Sports and social activities attended in person at least once a week_None of the above,16790,0.0112410923499071,0.010031705708256,-0.00842105083827478,0.0309032355380889,0.262492760138813
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29167#1.Sports and social activities attended in person at least once a week_Sports club or gym or fitness class,16790,-0.0323908553868608,0.0100729328213802,-0.052133803716766,-0.0126479070569555,0.00130403736282877
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29167#2.Sports and social activities attended in person at least once a week_Pub or social club,16790,-0.0456825641287701,0.0125423376910466,-0.0702655460032214,-0.0210995822543188,0.000271059709470198
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29167#3.Sports and social activities attended in person at least once a week_Religious group,16790,0.0618734553795204,0.0135670731745193,0.0352819919574626,0.0884649188015782,5.13782506379484e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29167#4.Sports and social activities attended in person at least once a week_Adult education class,16790,-0.0169991613356786,0.0219765996621929,-0.0600732966735767,0.0260749740022195,0.439230388702893
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29167#5.Sports and social activities attended in person at least once a week_Other group activity,16790,0.00688262605352351,0.0103739750274272,-0.0134503650002339,0.0272156171072809,0.507050748188136
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29168#0.Sports and social activities attended virtually at least once a week_None of the above,16785,0.00338123988948171,0.0113026144923025,-0.0187718845154311,0.0255343642943945,0.764825067548237
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29168#1.Sports and social activities attended virtually at least once a week_Sports club or gym or fitness class,16785,-0.0177171767108996,0.0165749202561298,-0.0502040204129139,0.0147696669911148,0.285123470387114
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29168#2.Sports and social activities attended virtually at least once a week_Pub or social club,16785,-0.0325350279116318,0.0253896053233076,-0.0822986543453147,0.0172285985220511,0.200060030166317
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29168#3.Sports and social activities attended virtually at least once a week_Religious group,16785,0.0761194970313948,0.0228551668094851,0.031323370084804,0.120915623977986,0.000868722541199621
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29168#4.Sports and social activities attended virtually at least once a week_Adult education class,16785,-0.000244861658912112,0.0334746048126513,-0.0658550870917087,0.0653653637738845,0.994163734460745
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29168#5.Sports and social activities attended virtually at least once a week_Other group activity,16785,0.00372783184621844,0.0162465043353855,-0.0281153166511371,0.0355709803435739,0.818518559583921
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29171.Frequency of feeling 'in tune' with people,16505,-0.0110745107336796,0.0294159156684564,-0.0687297054438541,0.046580683976495,0.706564753266818
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29172.Freuency of feeling that lacks companionship,16721,0.0426015337735805,0.0268616551872779,-0.0100473103934842,0.0952503779406452,0.11276711496492
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29173.Frequency of feeling left out,16634,0.0668792271175216,0.0278242740799901,0.012343649920741,0.121414804314302,0.0162441283011369
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29174.Frequency of feeling isolated from others,16697,0.0522615878128939,0.0287855611432607,-0.00415811202789704,0.108681287653685,0.0694575764994627
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29175.Tendency to bounce back quickly after hard times,16819,-0.0402659393280523,0.0238484064402487,-0.0870088159509399,0.00647693729483519,0.0913506957807783
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29176.Ability to make it through stressful events,16819,0.0222405859015898,0.0232411254996395,-0.0233120200777036,0.0677931918808832,0.338606459679407
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29177.Quick recovery from stressful events,16819,-0.010727286127954,0.0237017017005449,-0.057182621461022,0.0357280492051139,0.650845804361479
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29178.Hard to snap back when something bad happens,16819,0.00671187712060905,0.0233626720981622,-0.0390789601917888,0.0525027144330069,0.773893328484048
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29179.Comes through difficult times with little trouble,16819,-0.0186016877663928,0.023603301098572,-0.064864157919594,0.0276607823868083,0.430651162836296
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29180.Tendency to take a long time to get over setbacks,16819,-0.00586485581725461,0.0235212760583686,-0.0519665568916571,0.0402368452571479,0.803098839766261
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29181.General happiness,16725,0.0545314365584598,0.0244016261937128,0.00670424921878264,0.102358623898137,0.0254471964685463
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29182.Belief that own life is meaningful,16528,0.00521588319896961,0.024259385687542,-0.0423325127486127,0.0527642791465519,0.829766269241027
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X2926.Number of unsuccessful stop-smoking attempts,11227,0.0840069067398369,0.0281999878980733,0.0287349304596133,0.139278883020061,0.00289838897400964
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2946.Father's age,11021,-0.0108787021078671,0.00891422438448277,-0.0283505819014534,0.00659317768571911,0.222348659277851
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2966.Age high blood pressure diagnosed,12601,-0.0084160002469258,0.00686648235823987,-0.021874305669076,0.00504230517522435,0.220348074037844
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30000.White blood cell (leukocyte) count,48899,0.18039994781038,0.00283389524796888,0.174845513124361,0.185954382496399,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30010.Red blood cell (erythrocyte) count,48900,0.0115927991755432,0.00329655690228105,0.0051315476470723,0.018054050704014,0.000437444335151085
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30020.Haemoglobin concentration,48900,-0.0313243340227499,0.00352249512149988,-0.0382284244608897,-0.0244202435846101,6.16521777755292e-19
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30030.Haematocrit percentage,48900,-0.0202733524285711,0.00344433920781713,-0.0270242572758927,-0.0135224475812495,3.98248258350569e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30040.Mean corpuscular volume,48900,-0.0434021085537985,0.00290091645998784,-0.0490879048153746,-0.0377163122922223,1.69524372585087e-50
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30050.Mean corpuscular haemoglobin,48899,-0.0499338474451288,0.00290904909129097,-0.0556355836640591,-0.0442321112261985,7.57639202422389e-66
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30060.Mean corpuscular haemoglobin concentration,48899,-0.0225187992354004,0.00284589292654346,-0.0280967493714256,-0.0169408490993753,2.57050849943267e-15
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30070.Red blood cell (erythrocyte) distribution width,48900,0.012095371060802,0.00284365948722406,0.00652179846584289,0.0176689436557612,2.10890267286654e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30080.Platelet count,48900,0.171482403815947,0.00280558110298036,0.165983464854106,0.176981342777789,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30090.Platelet crit,48900,0.170351262384127,0.00287317983178902,0.164719829913821,0.175982694854434,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30100.Mean platelet (thrombocyte) volume,48900,-0.0523836109255081,0.00278386948405456,-0.057839995114255,-0.0469272267367612,1.04426148608188e-78
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30110.Platelet distribution width,48900,-0.0272687396108293,0.00282195744809707,-0.0327997762090996,-0.0217377030125591,4.52883670658755e-22
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30120.Lymphocyte count,48823,0.196003288924299,0.00276547523329186,0.190582957467047,0.201423620381551,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30130.Monocyte count,48823,0.101535839754072,0.00289241040325118,0.0958667153636999,0.107204964144444,1.23538666794707e-266
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30140.Neutrophill count,48823,0.112489632547221,0.00287081090546436,0.106862843172511,0.118116421921932,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30150.Eosinophill count,48823,0.0888145455952608,0.00280750788211305,0.0833118301463193,0.0943172610442024,1.96401743744658e-217
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30160.Basophill count,48823,0.316601464714539,0.015400055030708,0.286417356854351,0.346785572574726,1.6125724073898e-93
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30170.Nucleated red blood cell count,48823,0.309352170729811,0.0645436126603318,0.182846689915561,0.435857651544061,1.64856663329411e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30180.Lymphocyte percentage,48824,0.0622708286591598,0.00284352370351774,0.056697522200265,0.0678441351180546,8.5672447674701e-106
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30190.Monocyte percentage,48824,-0.0280619351947497,0.00289245118072079,-0.0337311395089624,-0.0223927308805369,3.10306679677706e-22
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30200.Neutrophill percentage,48824,-0.0524158602597231,0.00281950186422711,-0.0579420839136083,-0.046889636605838,7.08094958166205e-77
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30210.Eosinophill percentage,48824,0.0324110774314577,0.00280301295364759,0.0269171720423085,0.037904982820607,6.96664451418401e-31
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30220.Basophill percentage,48824,-0.00773802581613056,0.00279953084171533,-0.0132251062658926,-0.0022509453663685,0.00571112814712854
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30230.Nucleated red blood cell percentage,48822,0.306000353241457,0.0646490107070743,0.179288292255591,0.432712414227322,2.21564540654267e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30240.Reticulocyte percentage,48049,0.0334560572884535,0.00301126479888776,0.0275539782826335,0.0393581362942735,1.21146438735834e-28
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30250.Reticulocyte count,48049,0.0355652519847924,0.00307506110633738,0.0295381322163712,0.0415923717532137,6.75663669452256e-31
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30260.Mean reticulocyte volume,48049,-0.032202117657504,0.00286672588550252,-0.0378209003930889,-0.0265833349219191,3.05169177113533e-29
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30270.Mean sphered cell volume,48049,-0.042437498282706,0.00289192782028336,-0.0481056768104614,-0.0367693197549506,1.19776992697999e-48
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30280.Immature reticulocyte fraction,48049,0.0286633241327567,0.00300747493613967,0.0227686732579229,0.0345579750075904,1.63234502799098e-21
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30290.High light scatter reticulocyte percentage,48049,0.0378604229839355,0.00307351285581553,0.031836337786537,0.0438845081813339,8.15096711181199e-35
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30300.High light scatter reticulocyte count,48049,0.0393525370369475,0.00311925141289992,0.0332388042676636,0.0454662698062313,1.96864972394145e-36
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30500.Microalbumin in urine,15893,0.0223071662074409,0.005132775907965,0.0122469254278295,0.0323674069870523,1.394891044553e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30510.Creatinine (enzymatic) in urine,49003,0.020954182576483,0.0030554524068871,0.0149654958589843,0.0269428692939817,7.0674873528716e-12
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30520.Potassium in urine,48903,-0.00630018797461895,0.00284895556162981,-0.0118841408754134,-0.000716235073824528,0.0270125727711768
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30530.Sodium in urine,48889,0.00211883682374673,0.0029759253825667,-0.003713976926084,0.00795165057357747,0.476472762438111
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30600.Albumin,44086,-0.0623203983158118,0.00305230918091002,-0.0683029243103954,-0.0563378723212282,3.13070871676141e-92
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30610.Alkaline phosphatase,48106,0.0603468987552842,0.00292061430234863,0.0546224947226809,0.0660713027878876,1.94557792772081e-94
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30620.Alanine aminotransferase,48101,0.0183144939492585,0.00310494715103314,0.0122287975332335,0.0244001903652834,3.69294116472533e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30630.Apolipoprotein A,43811,-0.222625048336979,0.00318831826205756,-0.228874152130612,-0.216375944543346,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30640.Apolipoprotein B,47853,0.0426006578087736,0.00283641254188129,0.0370412892266862,0.0481600263908609,7.18161497943262e-51
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30650.Aspartate aminotransferase,47959,-0.0115305051258605,0.00294989976650132,-0.0173123086682031,-0.00574870158351792,9.28913622327783e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30660.Direct bilirubin,40818,-0.0579978652150495,0.00317734826161119,-0.0642254678078074,-0.0517702626222916,3.8297616740909e-74
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30670.Urea,48083,0.00642154988891166,0.00299637516125749,0.000548654572846975,0.0122944452049763,0.0321095842650276
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30680.Calcium,44083,0.00339181469768759,0.00297069165398243,-0.00243074094411797,0.00921437033949315,0.253560305538537
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30690.Cholesterol,48118,-0.0209565718063043,0.00288243917973305,-0.0266061525985811,-0.0153069910140276,3.63781139145192e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30700.Creatinine,48099,0.0119063037230418,0.003477441499337,0.00509051838434132,0.0187220890617424,0.000617878642341439
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30710.C-reactive protein,47974,0.0914250333342695,0.00315787228637637,0.0852356036529718,0.0976144630155672,1.01301533269193e-182
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30720.Cystatin C,48119,0.08204205167018,0.00330471476960946,0.0755648107217455,0.0885192926186146,3.36782365074539e-135
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30730.Gamma glutamyltransferase,48097,0.0230422252460778,0.00315757808871088,0.0168533721922044,0.0292310782999511,2.97819148041383e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30740.Glucose,44034,-0.00420849895216724,0.00305240184548977,-0.0101912065693272,0.00177420866499271,0.167978862867908
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30750.Glycated haemoglobin (HbA1c),47827,0.0820262554298844,0.00305387718385949,0.0760406561495198,0.088011854710249,9.68415972084597e-158
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30760.HDL cholesterol,44055,-0.248568422549467,0.0033063701556304,-0.255048908054503,-0.242087937044431,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30770.IGF-1,47869,-0.00824865101666194,0.00297283010397072,-0.0140753980204445,-0.00242190401287933,0.00552775397107384
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30780.LDL direct,48013,0.0198674184085535,0.00284480819486422,0.0142915943466196,0.0254432424704873,2.91138250678069e-12
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30790.Lipoprotein A,38460,-0.00979848621491741,0.00316044010467708,-0.0159929488200845,-0.00360402360975034,0.00193428499039167
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30810.Phosphate,43983,0.0461784395709117,0.00306788437810211,0.0401653861898316,0.0521914929519919,4.47759131653893e-51
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30830.SHBG,43667,-0.0674324936561658,0.0035240588288548,-0.0743396489607212,-0.0605253383516103,2.78697031095433e-81
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30840.Total bilirubin,47927,-0.0793650950544089,0.00299839951834325,-0.0852419581103617,-0.0734882319984561,2.79568105936573e-153
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30850.Testosterone,43465,-0.0277552905044277,0.00494866546089798,-0.0374546748077878,-0.0180559062010677,2.05157962982322e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30860.Total protein,44050,0.0157097316640165,0.00301733037871148,0.009795764121742,0.021623699206291,1.93298091588907e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30870.Triglycerides,48081,0.147710798098013,0.00301899957298055,0.141793558934971,0.153628037261055,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30880.Urate,48049,0.0342668735080524,0.00355321809984772,0.0273025660323509,0.041231180983754,5.46200008247429e-22
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30890.Vitamin D,45941,-0.0252170329314657,0.00320265774717732,-0.0314942421159333,-0.0189398237469982,3.51578193413266e-15
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X3137.Number of measurements made,45735,0.00690059924907038,0.0173461939794719,-0.0270979409506946,0.0408991394488353,0.690767435521835
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X3143.Ankle spacing width,28631,-0.00593430804451314,0.00509933253648371,-0.0159289998160212,0.00406038372699492,0.244538238116429
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,"X3144.Heel Broadband ultrasound attenuation, direct entry",28629,-0.00553126068954131,0.00392690401655397,-0.0132279925619871,0.00216547118290447,0.158977627756263
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X3146.Speed of sound through heel,28631,-0.015216393396904,0.00379309747617377,-0.0226508644502046,-0.00778192234360345,6.04615763577492e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,"X3147.Heel quantitative ultrasound index (QUI), direct entry",28631,-0.0122783207682735,0.00383316093747593,-0.0197913162057263,-0.00476532533082067,0.00136065759050416
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X3148.Heel bone mineral density (BMD),28610,-0.0124706984376568,0.00383827255621539,-0.0199937126478389,-0.0049476842274746,0.00115929142304444
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X3526.Mother's age at death,30061,-0.0115463493953579,0.00376985603749424,-0.0189352672288466,-0.00415743156186916,0.00219463761812685
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X3581.Age at menopause (last menstrual period),15539,-0.00306080337498776,0.00503633709060755,-0.0129320240725785,0.00681041732260304,0.543366200657803
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X3761.Age hay fever, rhinitis or eczema diagnosed",9932,0.00438881383319428,0.00650750191832863,-0.00836588992672983,0.0171435175931184,0.500057668063369
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4100.Ankle spacing width (left),16221,-0.000809714745709326,0.00673271890137479,-0.0140058437924039,0.0123864143009853,0.904274212816958
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4101.Heel broadband ultrasound attenuation (left),16217,-0.00106451795067932,0.00519600057646312,-0.011248679080547,0.00911964317918839,0.837674266195611
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4103.Speed of sound through heel (left),16221,-0.00849906659985474,0.00502094083063123,-0.0183401106278919,0.00134197742818248,0.0905272516524834
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,"X4104.Heel quantitative ultrasound index (QUI), direct entry (left)",16221,-0.00621774437561612,0.00507433201546168,-0.016163435125921,0.00372794637468878,0.220467741763229
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4105.Heel bone mineral density (BMD) (left),16209,-0.00643273042641955,0.00508006514310336,-0.0163896581069021,0.00352419725406303,0.205434904743197
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,"X4106.Heel bone mineral density (BMD) T-score, automated (left)",16221,-0.0062287173144993,0.0050743506130605,-0.0161744445160979,0.00371700988709929,0.219656108093201
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4119.Ankle spacing width (right),16210,0.000849174086448701,0.00662676748020569,-0.0121392901747545,0.0138376383476519,0.898037372040069
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4120.Heel broadband ultrasound attenuation (right),16209,0.00309744475275121,0.00521536277944533,-0.00712466629496163,0.0133195558004641,0.552582061876202
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4122.Speed of sound through heel (right),16210,-0.0049233865684115,0.00503391670198905,-0.01478986330431,0.00494309016748704,0.328067707418867
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,"X4123.Heel quantitative ultrasound index (QUI), direct entry (right)",16210,-0.00212759333763595,0.00509036828524364,-0.0121047151767135,0.0078495285014416,0.675978599219862
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4124.Heel bone mineral density (BMD) (right),16196,-0.00223100525187895,0.00509717447082952,-0.0122214672147048,0.00775945671094692,0.661613595766686
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,"X4125.Heel bone mineral density (BMD) T-score, automated (right)",16210,-0.00212756834209137,0.00509036995492996,-0.0121046934537541,0.00784955676957135,0.675982289588542
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4194.Pulse rate,16845,0.028956469025866,0.00484030314497898,0.0194694748617072,0.0384434631900248,2.24371674255396e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4195.Pulse wave reflection index,16845,-0.00839982798621923,0.00497115531689832,-0.0181432924073399,0.00134363643490147,0.0911013092369946
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4196.Pulse wave peak to peak time,16834,-0.017236280561082,0.00495074774189105,-0.0269397461351884,-0.00753281498697551,0.000499783833225428
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4198.Position of the pulse wave peak,16845,0.0122906489282582,0.00499456985608288,0.00250129201033576,0.0220800058461806,0.013872638879291
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4199.Position of pulse wave notch,16845,0.016037504408109,0.00484427010672305,0.00654273499893183,0.0255322738172862,0.000932875597904973
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4200.Position of the shoulder on the pulse waveform,16845,0.0208334342295042,0.00501923983244911,0.0109957241579039,0.0306711443011044,3.33068682134431e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4269.Number of triplets attempted (left),16533,0.0208155985965897,0.0743592581392874,-0.124928547356414,0.166559744549593,0.779532536456974
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4270.Volume level set by participant (left),16356,0.0282703717668349,0.023025705594978,-0.016860011199322,0.0734007547329918,0.219549357205651
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4276.Number of triplets attempted (right),16533,-0.0196123224043545,0.0721998920015485,-0.161124110727389,0.12189946591868,0.785902836352424
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4277.Volume level set by participant (right),16338,0.0496073134292558,0.0230723938428868,0.00438542149719769,0.0948292053613139,0.0315641477914672
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Cognitive function,X4288.Time to answer,16886,0.00897375477109013,0.00560719966187005,-0.00201635656617516,0.0199638661083554,0.109528897102493
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Cognitive function,X4290.Duration screen displayed,16886,0.00899740336419781,0.00511316383333196,-0.00102439774913283,0.0190192044775284,0.0784844717890262
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X46.Hand grip strength (left),50302,-0.042935083558295,0.00401993750063241,-0.0508141610595345,-0.0350560060570555,1.34074225761912e-26
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X47.Hand grip strength (right),50306,-0.0367569351878198,0.00398628867837462,-0.0445700609974341,-0.0289438093782056,3.05808300981578e-20
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X48.Waist circumference,50449,0.110289020465515,0.00619557266553972,0.0981456980410574,0.122432342889973,1.13777918302293e-70
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X4803.Tinnitus,16577,0.0562206928941654,0.0270137575265711,0.00327372814208598,0.109167657646245,0.0374320792858624
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X4825.Noisy workplace,16786,0.0492222450208339,0.0304384005255666,-0.0104370200092766,0.108881510050944,0.105873324568418
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X4836.Loud music exposure frequency,16684,0.0729370978537332,0.0382469833809835,-0.00202698957299445,0.147901185280461,0.0565374209997483
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X49.Hip circumference,50440,-0.0265627598750399,0.00497793981176688,-0.036319521906103,-0.0168059978439768,9.53785532970764e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X50.Standing height,50395,-0.0174013533035673,0.00395062884937071,-0.0251445858483339,-0.00965812075880066,1.06146147332011e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X5057.Number of older siblings,14814,0.00977255069419153,0.0247276598761095,-0.0386936626629832,0.0582387640513662,0.692695631687449
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X51.Seated height,50173,-0.00416347108943313,0.00365949628327847,-0.0113360838046589,0.00300914162579266,0.255244111890955
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5181.Ever had eye surgery,11383,-0.00105258873850219,0.056151866517273,-0.111110247112357,0.109005069635353,0.985044546184945
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5186.Duration visual-acuity screen displayed (right),11355,-0.0121476622238212,0.00587974451860485,-0.0236719614802867,-0.000623362967355665,0.038849368732102
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5188.Duration visual-acuity screen displayed (left),11352,-0.00929137761295347,0.00593729113983755,-0.0209284682470351,0.00234571302112812,0.117629894176682
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5190.Duration at which refractometer first shown (right),11230,-0.0129715193018582,0.00597824984149003,-0.0246888889911786,-0.0012541496125377,0.0300440304207283
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5193.Duration at which refractometer first shown (left),11226,-0.00967205610501632,0.00601239013886278,-0.0214563407771874,0.00211222856715472,0.107712872667858
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,"X5199.logMAR, initial (right)",11316,0.0263881812876378,0.0294033858426923,-0.0312424549640392,0.0840188175393147,0.369495916958563
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5200.Final number of letters displayed (right),11316,-0.041840673854145,0.192529304223783,-0.419198110132759,0.335516762424469,0.827962063774974
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,"X5201.logMAR, final (right)",11205,0.00341406365135451,0.00598676923734604,-0.00832000405384372,0.0151481313565527,0.568507306966697
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5202.Number of rounds to result (right),11316,0.0401555530011374,0.027721270247154,-0.0141781366832844,0.0944892426855593,0.147491999470495
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,"X5206.logMAR, initial (left)",11308,0.00760819752188243,0.0292691308475321,-0.0497592989392804,0.0649756939830453,0.794915331016329
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5207.Final number of letters displayed (left),11308,-0.31342437579605,0.152161305736868,-0.61166053504031,-0.015188216551789,0.0394389486949534
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,"X5208.logMAR, final (left)",11198,0.000203405389805297,0.00597891096758605,-0.0115152601066634,0.0119220708862739,0.972861430747068
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5209.Number of rounds to result (left),11302,0.00508613231931346,0.0278105605061367,-0.0494225662727145,0.0595948309113414,0.854891597830636
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,"X5254.Intra-ocular pressure, corneal-compensated (right)",10823,-0.00743150232573727,0.00597149067639009,-0.0191356240514619,0.0042726193999873,0.213343680471064
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,"X5255.Intra-ocular pressure, Goldmann-correlated (right)",10823,-0.00442993977305922,0.0059502960924501,-0.0160925201142614,0.00723264056814298,0.456595884041522
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5256.Corneal hysteresis (right),10823,0.00522567696025927,0.00601486750856669,-0.00656346335653144,0.01701481727705,0.384979454688362
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5257.Corneal resistance factor (right),10823,0.000343334785468165,0.0059859414453628,-0.0113891104474429,0.0120757800183792,0.954261989985812
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,"X5262.Intra-ocular pressure, corneal-compensated (left)",10800,-0.00288542390029056,0.00597170361229431,-0.0145899629803874,0.00881911517980629,0.62897582231007
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,"X5263.Intra-ocular pressure, Goldmann-correlated (left)",10800,-0.00507602987468377,0.00593905562178661,-0.0167165788933855,0.00656451914401799,0.392743782551687
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5264.Corneal hysteresis (left),10800,0.00248753276809864,0.00602646028571586,-0.00932432939190444,0.0142993949281017,0.67978446153461
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5265.Corneal resistance factor (left),10800,-0.00078431706414588,0.00598425631157679,-0.0125134594348364,0.0109448253065446,0.895727586974284
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X5364.Average weekly intake of other alcoholic drinks,11312,0.286628264865475,0.119366968635461,0.0526690063399717,0.520587523390977,0.0163558518315894
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,"X6144#1.Never eat eggs, dairy, wheat, sugar_Eggs or foods containing eggs",50291,0.0354543684441428,0.0160199691069495,0.00405522899452165,0.0668535078937639,0.0268927525434177
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,"X6144#2.Never eat eggs, dairy, wheat, sugar_Dairy products",50291,-0.0475663337511099,0.0174945753687348,-0.0818557014738301,-0.0132769660283898,0.00655181085096832
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,"X6144#3.Never eat eggs, dairy, wheat, sugar_Wheat products",50291,-0.00736107849634887,0.016603187471162,-0.0399033259398263,0.0251811689471286,0.65751209305987
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,"X6144#4.Never eat eggs, dairy, wheat, sugar_Sugar or foods or drinks containing sugar",50291,-0.0359745153005761,0.00711993654142188,-0.049929590921763,-0.0220194396793893,4.37255428217725e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,"X6144#5.Never eat eggs, dairy, wheat, sugar_I eat all of the above",50291,0.0259727610446939,0.00655163572333003,0.013131555026967,0.0388139670624207,7.37080914574483e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,"X6145#3.Illness, injury, bereavement, stress in last 2 years_Death of a close relative",22714,-0.014526556613177,0.00828410961339075,-0.0307634114554229,0.00171029822906888,0.0795220468069417
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,"X6145#4.Illness, injury, bereavement, stress in last 2 years_Death of a spouse or partner",22714,-0.0179438169684593,0.0226098572163906,-0.062259137112585,0.0263715031756663,0.427420291467037
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,"X6145#5.Illness, injury, bereavement, stress in last 2 years_Marital separation or divorce",22714,-0.0237107568850282,0.0161414578999633,-0.0553480143689563,0.00792650059889982,0.141864203267962
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,"X6145#6.Illness, injury, bereavement, stress in last 2 years_Financial difficulties",22714,0.0108958212638024,0.00981090700707337,-0.00833355647006144,0.0301251989976662,0.266759878515275
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X6147#1.Reason for glasses or contact lenses_For short-sightedness,50442,-0.0177340645857292,0.0110046943609954,-0.0393032655332801,0.00383513636182178,0.107077052930889
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X6147#2.Reason for glasses or contact lenses_For long-sightedness,50442,-0.0135452122689434,0.0141863977570791,-0.0413505518728185,0.0142601273349316,0.339682009134134
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X6147#3.Reason for glasses or contact lenses_For just reading or near work as you are getting older (called 'presbyopia'),50442,-0.0325756972956765,0.0108878225804612,-0.0539158295533804,-0.0112355650379727,0.00277346010808318
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X6147#4.Reason for glasses or contact lenses_For 'astigmatism',50442,-0.0755295554855055,0.0179767355343577,-0.110763957132847,-0.0402951538381644,2.65588017470206e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X6147#5.Reason for glasses or contact lenses_For a 'squint' or 'turn' in an eye since childhood (called 'strabismus'),50442,0.0379680344181835,0.0433344627249243,-0.0469675125226681,0.122903581359035,0.380945832609366
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X6147#6.Reason for glasses or contact lenses_For a 'lazy' eye or an eye with poor vision since childhood (called 'amblyopia'),50442,0.00241235510311166,0.0301849560186174,-0.0567501586933784,0.0615748688996017,0.936301900541359
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X6147#7.Reason for glasses or contact lenses_Other eye condition,50442,0.119196184711265,0.0467311208959206,0.027603187755261,0.21078918166727,0.0107541942830226
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6149#1.Mouth or teeth dental problems_Mouth ulcers,50290,-0.012373018374736,0.00910434420480446,-0.0302175330161527,0.00547149626668078,0.174145215848549
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6149#2.Mouth or teeth dental problems_Painful gums,50290,0.0485420945622376,0.015548649440563,0.0180667416587341,0.079017447465741,0.00179759724279232
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6149#3.Mouth or teeth dental problems_Bleeding gums,50290,0.0157190609295942,0.0081714372347334,-0.00029695605048324,0.0317350779096717,0.0544029469502242
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6149#4.Mouth or teeth dental problems_Loose teeth,50290,0.0588302636634803,0.0137028293364824,0.0319727181639747,0.0856878091629859,1.76371609652761e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6149#5.Mouth or teeth dental problems_Toothache,50290,0.0449653708881185,0.0135406761549845,0.018425645624349,0.0715050961518881,0.000898357549923259
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6149#6.Mouth or teeth dental problems_Dentures,50290,0.0586210799264001,0.0076309290037236,0.0436644590791018,0.0735777007736983,1.59404216249336e-14
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6150#1.Vascular or heart problems diagnosed by doctor_Heart attack,15665,0.0688424633557775,0.0182840266426769,0.0330057711361308,0.104679155575424,0.000167044753784682
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6150#2.Vascular or heart problems diagnosed by doctor_Angina,15665,0.0385144729014397,0.0156371565995991,0.00786564596622543,0.0691632998366539,0.0137882923729049
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6150#3.Vascular or heart problems diagnosed by doctor_Stroke,15665,0.0522576225343856,0.0215521773875711,0.0100153548547462,0.094499890214025,0.0153321725517566
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6150#4.Vascular or heart problems diagnosed by doctor_High blood pressure,15665,-0.0386298631748639,0.0172140486563316,-0.0723693985412739,-0.00489032780845391,0.0248405726631634
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6151#1.Fractured bone site(s)_Ankle,50231,0.00824682348311915,0.0231961927550137,-0.0372177143167077,0.053711361282946,0.72219790777074
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6151#2.Fractured bone site(s)_Leg,50231,0.0142851952840983,0.0344745257191283,-0.0532848751253931,0.0818552656935896,0.678605222037863
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6151#3.Fractured bone site(s)_Hip,50231,0.034956478266089,0.0609260161970235,-0.0844585134800771,0.154371470012255,0.566137597258321
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6151#4.Fractured bone site(s)_Spine,50231,-0.0470412080088031,0.058951951243447,-0.162587032445959,0.068504616428353,0.424898372033657
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6151#5.Fractured bone site(s)_Wrist,50231,-0.0419377837727928,0.0201010931636678,-0.0813359263735818,-0.00253964117200383,0.0369525574701701
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6151#6.Fractured bone site(s)_Arm,50231,0.0340628660255411,0.0270755311020837,-0.0190051749345429,0.0871309069856252,0.208372924226891
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6151#7.Fractured bone site(s)_Other bones,50231,-0.0266776754248527,0.0124342929809014,-0.0510488896674195,-0.00230646118228586,0.0319183149125044
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6152#5.Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor_Blood clot in the leg (DVT)",16287,0.0583262855974469,0.0199900894056193,0.019145710362433,0.0975068608324608,0.0035303774062501
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6152#6.Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor_Emphysema or chronic bronchitis",16287,0.0372085106916606,0.0214402153954458,-0.00481431148341307,0.0792313328667343,0.0826793271349477
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6152#7.Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor_Blood clot in the lung",16287,0.0594416211277697,0.0291399732214608,0.0023272736137065,0.116555968641833,0.041379854731699
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6152#8.Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor_Asthma",16287,0.0129152245815801,0.0102771895056859,-0.00722806684956422,0.0330585160127244,0.208884537475931
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6154#1.Medication for pain relief, constipation, heartburn_Aspirin",22869,0.0163908294255274,0.00939129600964888,-0.00201611075338445,0.0347977696044392,0.0809423862649129
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6154#2.Medication for pain relief, constipation, heartburn_Ibuprofen",22869,-0.0360953153082248,0.00914584552692378,-0.0540211725409954,-0.0181694580754542,7.94942188200447e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6154#3.Medication for pain relief, constipation, heartburn_Paracetamol",22869,0.0207091724077877,0.00837786217049389,0.0042885625536197,0.0371297822619558,0.0134472307920447
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6154#4.Medication for pain relief, constipation, heartburn_Ranitidine",22870,0.0220363761228017,0.0198105405108424,-0.0167922832784493,0.0608650355240528,0.265996759651135
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6154#5.Medication for pain relief, constipation, heartburn_Omeprazole",22870,0.0282882894028703,0.0118794219909582,0.00500462230059219,0.0515719565051484,0.0172604969965765
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6154#6.Medication for pain relief, constipation, heartburn_Laxatives",22870,0.0261631927919253,0.016092170312633,-0.00537746102083528,0.057703846604686,0.103998824022745
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6155#1.Vitamin and mineral supplements_Vitamin A,50290,-0.00773710153635658,0.0190083384361674,-0.0449934448712448,0.0295192417985316,0.683982372831096
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6155#2.Vitamin and mineral supplements_Vitamin B,50290,0.00878801550515217,0.0133683093493206,-0.0174138708195163,0.0349899018298206,0.510941718801542
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6155#3.Vitamin and mineral supplements_Vitamin C,50290,0.0828907038400533,0.0367739267873435,0.0108138073368601,0.154967600343247,0.0241965672280359
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6155#4.Vitamin and mineral supplements_Vitamin D,50290,-0.030363281782074,0.0137384223590188,-0.0572905896057509,-0.00343597395839717,0.0271027378546085
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6155#5.Vitamin and mineral supplements_Vitamin E,50290,-0.0133513017821625,0.0156181127528026,-0.0439628027776556,0.0172601992133305,0.392632662723593
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6155#6.Vitamin and mineral supplements_Folic acid or Folate (Vit B9),50290,-0.00526316966448454,0.0180219403108641,-0.0405861726737781,0.030059833344809,0.770255454789672
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6155#7.Vitamin and mineral supplements_Multivitamins + or - minerals,50290,-0.0103180141537377,0.00592867083327495,-0.0219382089869566,0.00130218067948117,0.0818021624694842
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X6157#1.Why stopped smoking_Illness or ill health,9788,0.0150819597683392,0.0174924004513164,-0.019203145116241,0.0493670646529193,0.388598242321959
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X6157#2.Why stopped smoking_Doctor's advice,9788,0.0646833802016653,0.021826298569524,0.0219038350053983,0.107462925397932,0.00304843450011426
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X6157#3.Why stopped smoking_Health precaution,9788,-0.0427337875054492,0.0154905482770227,-0.0730952621284137,-0.0123723128824846,0.00581395749986679
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X6157#4.Why stopped smoking_Financial reasons,9788,0.0397139381675015,0.0138374451012846,0.0125925457689837,0.0668353305660194,0.0041130828318343
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6159#1.Pain type(s) experienced in last month_Headache,50516,0.0415498338070912,0.00696854444345794,0.0278914866979137,0.0552081809162688,2.50077643325614e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6159#2.Pain type(s) experienced in last month_Facial pain,50516,0.036282961903452,0.0201226178522273,-0.00315736908691357,0.0757232928938176,0.0713794865465022
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6159#3.Pain type(s) experienced in last month_Neck or shoulder pain,50516,0.0165237488747658,0.00651156506203972,0.00376108135316799,0.0292864163963637,0.0111645210620773
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6159#4.Pain type(s) experienced in last month_Back pain,50516,0.0148188201412709,0.00630030009319626,0.00247023195860627,0.0271674083239356,0.0186724948206391
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6159#5.Pain type(s) experienced in last month_Stomach or abdominal pain,50516,0.0545120331232591,0.00973944528626828,0.0354227203621732,0.0736013458843449,2.19175016742182e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6159#6.Pain type(s) experienced in last month_Hip pain,50516,0.00908738097238014,0.00870309917811872,-0.00797069341673254,0.0261454553614928,0.296418869469885
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6159#7.Pain type(s) experienced in last month_Knee pain,50516,0.000602536002792767,0.006778162547386,-0.0126826625900838,0.0138877345956693,0.929166736471081
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6159#8.Pain type(s) experienced in last month_Pain all over the body,50516,0.113423018315928,0.0199633722898744,0.0742948086277739,0.152551228004082,1.34207085916426e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X6160#1.Leisure or social activities_Sports club or gym,34967,-0.0473802005673204,0.00687553414654765,-0.0608562474945538,-0.033904153640087,5.62879188471454e-12
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X6160#2.Leisure or social activities_Pub or social club,34967,-0.0269372071468845,0.0071818562561195,-0.0410136454088787,-0.0128607688848902,0.000176604582035827
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X6160#3.Leisure or social activities_Religious group,34967,0.032313414191453,0.0080956433858742,0.0164459531551396,0.0481808752277665,6.58025084033459e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X6160#4.Leisure or social activities_Adult education class,34968,0.00546185178626096,0.0111164084789753,-0.0163263088325306,0.0272500124050526,0.62319444438399
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X6160#5.Leisure or social activities_Other group activity,34968,0.022800302304071,0.00726045066066718,0.00856981900916334,0.0370307855989787,0.00168890952755835
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X6162#1.Types of transport used (excluding work)_Car or motor vehicle,50054,0.0200579661787928,0.00699421062748932,0.00634931334891374,0.0337666190086719,0.00413515199178028
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X6162#2.Types of transport used (excluding work)_Walk,50054,-0.0133054884628423,0.00556985170084499,-0.0242223977964985,-0.00238857912918608,0.0169053110132886
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X6162#3.Types of transport used (excluding work)_Public transport,50054,0.00242973776186771,0.00618070523762853,-0.00968444450388422,0.0145439200276196,0.694235046735007
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X6162#4.Types of transport used (excluding work)_Cycle,50054,-0.0566015626689097,0.011175661828899,-0.0785058598535516,-0.0346972654842677,4.10457741959631e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X6164#1.Types of physical activity in last 4 weeks_Walking for pleasure (not as a means of transport),50089,-0.0241989125366595,0.00615325006262061,-0.0362592826593959,-0.0121385424139231,8.41086249828775e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X6164#3.Types of physical activity in last 4 weeks_Strenuous sports,50089,-0.0785943657415967,0.00960201044472742,-0.0974143062132624,-0.059774425269931,2.78194248955611e-16
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6179#1.Mineral and other dietary supplements_Fish oil (including cod liver oil),50290,0.00804419822004199,0.00605738023058762,-0.00382826703190974,0.0199166634719937,0.184184284387898
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6179#2.Mineral and other dietary supplements_Glucosamine,50290,-0.0169730132208802,0.00717647376003097,-0.0310389017905409,-0.00290712465121946,0.018029417582374
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6179#3.Mineral and other dietary supplements_Calcium,50290,-0.0315526327663767,0.0108280527003814,-0.0527756160591242,-0.0103296494736293,0.00357020155665614
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6179#4.Mineral and other dietary supplements_Zinc,50290,-0.0100904064947703,0.0136919486954502,-0.0369266259378527,0.0167458129483122,0.461150647322643
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6179#5.Mineral and other dietary supplements_Iron,50290,0.0119627574804138,0.0149449700645054,-0.0173293838460168,0.0412548988068444,0.423451726358317
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6179#6.Mineral and other dietary supplements_Selenium,50290,-0.0175222614868126,0.0178583360614881,-0.0525246001673292,0.0174800771937041,0.326508173341622
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,"X78.Heel bone mineral density (BMD) T-score, automated",28631,-0.0122786540108002,0.00383316469340629,-0.0197916568098766,-0.00476565121172392,0.00136026184320207
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X864.Number of days or week walked 10+ minutes,49422,-0.0755296906580446,0.0133502956792334,-0.101696270189342,-0.0493631111267471,1.54414753237591e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X874.Duration of walks,42837,-0.00867296215818278,0.0029755704411413,-0.0145050802228197,-0.00284084409354583,0.00356189245496979
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X884.Number of days or week of moderate physical activity 10+ minutes,47783,-0.0810969452201829,0.0129671619950602,-0.106512582730501,-0.055681307709865,4.03386334827033e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X894.Duration of moderate activity,37019,-0.0742090296284807,0.0158075115213217,-0.105191752210271,-0.0432263070466902,2.68160875909029e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X90087.No-wear time bias adjusted average acceleration,10543,-0.0185068408757355,0.00634626042504205,-0.0309455113088179,-0.00606817044265313,0.00355093282016333
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X904.Number of days or week of vigorous physical activity 10+ minutes,47689,-0.120878516471506,0.0134230712286089,-0.147187736079579,-0.0945692968634324,2.22844266895962e-19
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X914.Duration of vigorous activity,26718,-0.00987127044352224,0.00374653371954196,-0.0172144765338245,-0.00252806435322001,0.00842418613775203
